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INTRODUCTION:[1,2,3] 
Corneal diseases are a major cause of visual loss and blindness 
globally, second only to cataract. Ophthalmic mycoses are being 
increasingly recognised as an important cause of ocular morbidity and 
blindness and keratomycosis is the most frequent presentation. A larger 
proportion of keratitis is reported from developing countries than in 
developed countries. Bacteria, fungi and acanthamoeba are important 
aetiological agents in the developing world.  Of these organisms that 
cause keratitis, fungi remain to be one of the most elusive and 
challenging organisms to diagnose and treat. 
The incidence of mycotic keratitis in tropical and sub- tropical 
countries is more than 50% of all culture proven cases of keratitis. In 
mycotic keratitis, two types have been recognised: Keratitis due to 
filamentous fungi (especially Fusarium and Aspergillus), which 
commonly occurs in tropical and subtropical zones, and associated with 
corneal trauma (and concurrent contamination with vegetative material); 
and keratitis due to yeast‑like and related fungi particularly Candida; and 
mostly associated with corneal disease, local immunosuppression caused 
by chronic corticosteroid use and systemic disease conditions that lower 
the host resistance. Ocular trauma is a major predisposing factor for 
fungal keratitis and most cases are reported from developing countries 
such as India and Ghana. 
2 
CLASSIFICATION OF FUNGI:[2,7,10,22] 
Fungi are eukaryotic and heterotrophic organisms. The pathogenic 
fungi causing significant keratitis can be divided as follows: 
1. Filamentous fungi 
2. Yeast 
3. Dimorphic fungi 
 
FILAMENTOUS FUNGI: 
Filamentous fungi also known as molds, they appear as long 
filaments, called hyphae, which grow by apical extension and form 
feathery aerial colonies above the culture media. They are further sub 
classified into septate and non- septate organisms. The septate 
filamentary fungi are the most common cause of mycotic keratitis. They 
are divided into non- pigmented monilial (Fusarium spp, Aspergillus spp 
and Acremonium spp) and pigmented dematiaceous (Curvularia spp, 
Lasiodiplodia spp) types. The non-septate filamentary fungi (Mucor, 
Rhizopus spp and Absidia) are important causes of orbital diseases and 
endogenous endophthalmitis, but do not commonly cause corneal disease. 
 
YEASTS: 
Yeasts are fungi with the usual and dominant growth as unicellular 
organisms and produce creamy, pasty colonies, which may be mistaken 
for staphylococcal colonies. They divide by sexual budding, forming 
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pseudo- hyhae and do not form mycelium in culture. The most common 
fungi in this type are the Candida spp and Cryptococcus spp, which are 
part of the normal flora of skin, respiratory tract and conjunctiva and act 
as opportunistic pathogens. 
 
DIMORPHIC FUNGI: 
These fungi possess two distinct morphologic forms: the yeast 
phase which occurs in tissues and a mycelia phase which occurs in media 
and natural surfaces. They include Blastomyces, Coccidiodes, 
Histoplasma and Sporothrix and they exhibit properties those of molds 
when cultivated at 25ºC and those of yeasts when cultivated at 37º C. The 
dimorphic fungi are a rare cause of mycotic keratitis. 
 
RISK FACTORS:[2,9,12,16,21] 
Fungi are ubiquitous organisms present almost everywhere in the 
environment. In fact they have been isolated from the conjunctival sac in 
3% to 28% of healthy eyes in various studies. Despite the eye being 
constantly exposed to these pathogens, the normal defence mechanisms 
such as the eyelids, tear components and the corneal epithelium provide 
adequate protection. The fungi are unable to penetrate an intact, normal 
epithelium. An epithelial defect is a prerequisite for these organisms to 
initiate an infection. The various risk factors include: 
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I. OCULAR FACTORS: 
1. Trauma 
2. Chronic corneal inflammation 
 Herpes simplex 
 Herpes zoster 
 Vernal allergic conjunctivitis 
 Dry eye 
 Ocular surface disorders 
 Bullous keratopathy 
 Exposure keratopathy 
3. Contact lens wear 
4. Drugs 
 Corticosteroids 
 Anaesthetics 
5. Corneal surgery 
 Penetrating keratoplasty 
 Refractive surgery 
 
II. SYSTEMIC FACTORS 
 Diabetes mellitus 
 AIDS 
 Leprosy 
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Corneal trauma has been documented as the most common risk 
factor for mycotic keratitis in most of the studies. Corneal injury with 
vegetable matter or organic matter is reported in 55 to 65% of fungal 
keratitis. Agricultural workers in a rural setting and people working in 
warehouses storing agricultural products, especially onions and 
groundnuts are at an increased risk since the filamentous fungi are found 
in abundance in relation to these products. 
Contact lens wear is an uncommon risk factor in fungal keratitis. 
These fungi have been shown to grow within the matrix of soft contact 
lenses. Filamentous fungi are more commonly associated with cosmetic 
lens wear and yeasts from therapeutic lens use. Corticosteroids appear to 
increase the virulence of fungi and its use has been associated with the 
development and worsening of fungal keratitis. Other factors 
uncommonly reported include vernal or allergic keratoconjunctivitis, 
exposure keratopathy, neurotrophic ulcers and penetrating keratoplasty. 
The predisposing factors for the development of fungal keratitis after 
penetrating keratoplasty include suture related problems, topical steroid 
use, contact lens wear, graft failure and persistent epithelial defects. 
Fungal corneal ulcers have also been reported following refractive 
surgical procedures like radial keratotomy, photo-refractive keratotomy 
and more recently following Laser in situ keratomileusis (LASIK) 
procedures. 
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PATHOGENESIS:[23,24] 
The exact mechanisms underlying the pathogenesis of fungal 
infections are unclear. As compared to bacteria, the fungi are relatively 
non-immunogenic, partly because of their large size, which prevents them 
from being engulfed by the neutrophils, and partly because they do not 
secrete chemotactic factors, which attract inflammatory cells. After 
entering through a corneal epithelial defect, the fungi elaborate toxic 
substances and enzymes such as proteases, hemolysins and exotoxins. 
This invasion causes an innate and adaptive immune-mediated 
inflammation, resulting in tissue necrosis of the surrounding area. Fungi 
penetrate further into the stromal layers of the cornea causing tissue 
damage, scarring, and consequent opacification of the cornea. Fusarium 
spp, particularly, are known to possess specific cellular and molecular 
attributes, which aids them to cause virulent reaction. They can also 
adhere to biopolymers and have the ability to produce toxins and 
elaborate enzymes. The last in particular is thought to cause and 
potentiate Fusarial keratitis. Other toxins such as trichothene toxins elicit 
an inflammatory response even at low doses and cause destruction of 
many cell types at higher concentrations. 
A few species of Aspergillus produce aflatoxins and ochratoxins. 
The conidia of Aspergillus fumigatus have been shown to bind to and 
degrade the basement membrane laminin, an extracellular matrix 
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glycoprotein found in basement membranes. They have the capacity to 
penetrate an intact Descemet’s membrane. The resultant host 
inflammatory response subsequently contributes to the tissue damage. 
Activation of the complement system leads to concentration of 
polymorphonuclear inflammatory cells in the cornea.  
 
CLINICAL FEATURES:[2,7,10,17,29] 
Kaufman and Wood described the salient clinical features of 
mycotic keratitis in 1965. Some of the features like satellite lesions, 
presumed immune rings and endothelial plaques are probably not unique 
to fungal keratitis but are general features of a stromal inflammatory 
response in the cornea. 
However, there are two features that lead on to suspect a fungal cause: 
 Stromal infiltrate with feathery hyphate margins. 
 Infiltrates that tend to be dry, gray and elevated above the level of 
the corneal surface.  
 
OTHER FEATURES: 
 Insidious onset 
 Gradually progressive 
 May or may not be associated with epithelial defects  
 Presence of satellite lesions 
 Presence of endothelial plaque 
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 May be associated with an immune ring 
 Pigment deposition around the margins 
 Presence of solid and cheesy hypopyon 
 Descemet’s folds 
 Posterior corneal abscess 
 Associated lid edema and chemosis 
 
GENERAL SYMPTOMS: 
The onset of fungal keratitis is almost always insidious. Symptoms 
are usually non-specific, although possibly more prolonged duration (5 to 
10 days). Patients in general complain of a foreign body sensation for 
several days with a slow onset of increasing pain and diminution of vision 
especially if the keratitis involves the visual axis. 
 
GENERAL SIGNS: 
On slit lamp examination, the infiltrates appear greyish white or 
yellowish white and the base of the ulcer is often filled with soft, creamy 
and raised exudates. The fungal ulcers have characteristic findings, which 
include elevated areas, hyphate (branching) ulcers, irregular feathery 
margins, a dry rough texture, and satellite lesions. Feathery borders or 
hyphate edges are seen in 70% of the patients and satellite lesions are 
seen in 10 % of the patients. Hypopyon is generally fixed and may be 
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present in 45% to 66% of the cases. An immune ring, endothelial plaque 
and a posterior corneal abscess may also be present. 
 
FILAMENTARY FUNGI: 
Unlike bacterial infections, there is less pain, conjunctival 
congestion, discharge and chemosis early in the course of fungal infection 
and the symptoms are far less than what is expected of the size of the 
ulcer. Indeed, it may take several days before the patient seeks medical 
care. The earliest finding may be a small non-specific stromal infiltrate 
with a surrounding dry, sick looking epithelium, in which case it is 
indistinguishable from a bacterial infection. Commonly the patient 
presents with a central or a para-central ulcer with feathery margins. The 
most common misdiagnosis, which might be made at this stage, may be a 
dendritic keratitis caused by herpes simplex. These pseudodendritic 
lesions are shorter, stockier and are associated with surrounding stromal 
infiltration and greyish yellow. In addition, a mirror image of the 
pseudodendritic lesion in the deeper stromal layers can also be seen. The 
adjacent Descemet’s membrane may be thrown into folds. As time 
progresses, the ulcer starts to become larger and elevated above the level 
of the corneal surface. The edges of the ulcer appear irregular, somewhat 
feathery. The surface looks dirty white and dry and have a soft texture 
except in pigmented fungi. The serrated edges and the dry elevated 
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surface can be considered pathognomonic of a fungal cause. The stromal 
lesions are present beyond the size of the epithelial defect and have a 
feathery pattern. In rare instances the lesion may be entirely in the 
posterior aspect of the stroma without an accompanying epithelial defect. 
In these cases, the posterior stromal lesions also have a feathery edge. 
Foci of infiltration can be seen several millimetres away from the main 
area of involvement. These are called satellite lesions and they may 
remain isolated from the main lesion or may be connected with the main 
ulcer by a thin line of stromal infiltration. The epithelium can be intact 
over the infiltrate. An endothelial plaque can be an accompanying 
finding. Like in many other keratitis, a ring infiltrate surrounds the 
primary lesion, most likely representing an antibody response to the 
fungal antigen. Less commonly, the entire lesion can start in the 
periphery and progress to form a ring infiltration and a ring abscess. 
Hypopyon can be seen in varying proportions and the amount is not 
directly proportional to the size of the ulcer. As the lesion progresses, the 
pain starts to get intense mostly due to secondary glaucoma and the ulcer 
starts to involve almost the whole of the cornea and starts to lose its 
characteristic pattern. The lesions look more suppurative. The edges of 
the ulcer may start becoming rounded like a bacterial ulcer, but the edges 
of the deeper stromal lesions have characteristic feathery pattern until the 
final course of the disease. As the size of the ulcer becomes larger, it 
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becomes more flushed with the surface and assumes a smooth surface. A 
significant majority of the deeper stromal ulcers may perforate over time. 
 
LABORATORY DIAGNOSIS:[17,22,26-30] 
Corneal ulcer scrapings from the ulcer edge and the base form the 
mainstay of the diagnosis of a case of fungal keratitis. Corneal scraping 
with a Kimura spatula or a surgical blade is preferred to the use a calcium 
alginate, dacron/ rayon swab, or a sponge-type material. The organisms 
may be deeper in the tissues and may not be accessible to a more 
superficial scraping. Corneal scraping not only provides diagnostic clues 
but also may be therapeutic as it also aids in the initial debridement and 
debulking of the organisms. Further, it also breaches the epithelium, 
which may provide better penetration of the anti-fungal agents. Cultures 
should also be sent from topically applied medications, cosmetics, contact 
lenses and their storage and cleaning solutions, wherever indicated. These 
items should be obtained from the patient at the initial visit. Apart from 
this anterior chamber tap and corneal biopsy may be done especially in 
cases of deep stromal keratitis and endothelial plaques. Laboratory 
diagnosis of fungal keratitis primarily includes direct microscopy, fungal 
cultures and newer diagnostic modalities such as Polymerase Chain 
Reaction (PCR) and Confocal microscopy. Presumptive identification of 
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fungi are based on the morphologic characteristics of hyphal forms and 
the size. 
 
MORPHOLOGY OF FILAMENTOUS FUNGI: 
FUSARIUM: 
The Fusarium fungi are characterised by distinctive macroconidia 
and microconidia with the major identifying morphologic feature being 
the large banana shaped macroconidia that are produced on the short 
lateral hyphae or conidiospores.  
 
ASPERGILLUS: 
The conidiophore in Aspergillus fungi have a swollen terminal end, 
surrounded by flask shaped sterigmata, each of which produces long 
chains of coccoid conidia that radiate out from the terminal end, is highly 
diagnostic. The hyphae are septate and characteristically branch 
dichotomously.  
LABORATORY TECHNIQUES: 
1. Direct Microscopy: 
Direct microscopy uses 10% KOH (Potassium Hydroxide) wet mount 
preparation and smears, which are stained by Gram and Giemsa stain. 
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a. KOH Wet Mount Preparation: 
10 % KOH wet mount is simple, cheap, rapid and easy to interpret and 
is particularly useful in tropical countries. The fungal elements are 
colourless with this technique. KOH smear has a sensitivity of 72.2% to 
91%. 
 
b. Gram’s stain: 
Gram’s stain is equally sensitive in detecting fungal organisms. 
Gram’s stain identifies fungal species in 31.6% to 98%. 
 
c. Giemsa stain: 
The internal contents of filamentous fungi are blue and cell walls and 
septation if present are hyaline. Giemsa stain identifies fungal elements in 
27% to 85% of the cases. 
 
5. Lactophenol cotton blue: [28] 
Lactophenol cotton blue has a sensitivity of 70 to 80 % in cases of 
fungal keratitis. The preparation has three components: phenol, which 
will kill any live organisms; lactic acid which preserves fungal structures, 
and cotton blue which stains the chitin in the fungal cell walls. 
 
6. Grocott’s methenamine silver stain: 
Grocott’s methenamine silver staining has a sensitivity of 89%.  
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FUNGAL CULTURE: 
Culture media for suspected fungal keratitis should include the 
same culture media used for a general microbial keratitis workup. Sheep 
blood agar, Sabouraud dextrose agar (without cycloheximide) and 
thioglycolate broth should be inoculated. Sabouraud dextrose agar should 
contain 50 micrograms /ml gentamicin and should be without 
cycloheximide as the latter inhibits saprophytic fungi. Thioglycolate 
broth is inoculated for the possible growth of anaerobic bacteria at 35ºC 
to 37ºC. A definitive diagnosis of fungal keratitis is made if: 
1. Corneal scrapings reveal fungal elements in smears, 
2. Fungus grows in more than one medium in the absence of fungus 
in smears, 
3. Fungus grows on a single medium in the presence of fungus in 
smears, 
4. Confluent growth of fungus appears at the inoculated site on a 
single solid medium. 
A fungus grown on the primary isolation medium may be 
subcultured onto a potato dextrose agar (PDA) medium and incubated for 
a period of 10 days to facilitate sporulation. Following adequate growth 
of the fungal isolate on PDA, the identification may be carried out based 
on its macroscopic and microscopic features. Positive cultures should be 
expected in 52 to 68 % of cases. Initial growth occurs within 72 hours in 
15 
83% of cultures and within 1 week in 97% of culture. Most in fact are 
visible with dissecting microscope or naked eye within 36 hours. But we 
should wait for at least a week before declaring a culture negative for 
fungi. Both yeast and hyphae readily grow in sheep blood agar and 
Sabouraud dextrose agar at room temperature. Increasing the humidity of 
the medium by placing the inoculated agar plates in plastic bags has also 
been recommended for enhancement of fungal growth. 
 
CULTURAL CHARACTERISTICS: 
FUSARIUM: 
The colonies of Fusarium organisms are usually white in the early 
stages of development but often acquire a buff coloration. As the colonies 
mature, a variety of colour pigments ranging from yellow to red to purple 
are produced. Pigments that are secreted onto the agar are best seen on 
the undersurface of the colony. This is known as reverse pigmentation. 
 
ASPERGILLUS: 
 Aspergillus is a large genus with many species but two are 
particularly prominent, Aspergillus fumigatus and Aspergillus niger. 
Colonies of A. fumigatus are white at first, but as spores are produced 
they become velvet green owing to the pigmentation of the conidia. A. 
fumigatus is able to tolerate unusually high temperatures and can grow in 
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vitro at 50ºC. A. niger colonies are also white during the initial growth 
phase but turn completely black as they undergo sporulation. 
 
NEWER DIAGNOSTIC MODALITIES: 
More recent methods for the identification of fungi, although still 
not widely available, include immunofluorescence staining, electron 
microscopy, polymerase chain reaction and confocal microscopy. These 
newer diagnostic modalities may not be available at all places. 
 
POLYMERASE CHAIN REACTION: 
The technique requires only 4 hours to obtain results, quicker than 
the 2 days to 2 weeks required by culture methods and in future may 
become a valuable adjunctive tool for the diagnosis of fungal keratitis, 
although it cannot replace culture methods as the possibility of false 
positive results needs to be considered. 
 
CONFOCAL MICROSCOPY:[29,30] 
Confocal microscopy has recently been used in cases of fungal 
keratitis, which helps to identify the hyphal elements and the yeasts. 
Confocal microscopy is an imaging technique that allows optical 
sectioning of almost any material, with increased axial and lateral spatial 
resolution and better image contrast, which may be useful for the 
identification of corneal pathogens in the early stages of infection. In 
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clinical keratitis due to Aspergillus spp., fungal hyphae can be imaged as 
high-contrast filaments, 60 to 400Å long and 6Å wide. In patients with 
mycotic keratitis, in vivo scanning slit confocal microscopy helps in 
establishing the diagnosis and demonstrating the non-responsiveness to 
medical therapy by showing an increased load of fungal filaments, 
therefore aiding the treatment decision. Thus, confocal microscopy is a 
potentially useful, non-invasive technique to determine the presence of 
fungal hyphae in vivo within the human cornea. Limitations in the use of 
this technique for routine diagnosis relate to instrument configuration, 
movement of either the tissue or the microscope, difficulty in 
reproducibly returning to the area of interest for serial examination, lack 
of a distinctive morphology of some pathogens, and limited resolution of 
the microscope. 
 
KERATECTOMY /BIOPSY: 
If corneal scrapings for smears and cultures are negative, a 
diagnostic superficial keratectomy or corneal biopsy may become 
necessary. The biopsy can be performed in the minor operating room or 
at the slit lamp under topical anaesthesia using 0.5 % proparacaine and 2 
% xylocaine eye drops. In some cases, eyelid and retrobulbar anaesthesia 
may be required. Under the microscope, a round 2 to 3mm sterile 
disposable dermatologic trephine is used and partial thickness 
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trephination is done in such a manner so that it encompasses both the 
clinically infected area and the adjacent clear cornea. The base is then 
undermined with a surgical blade to complete the lamellar keratectomy. 
The corneal biopsy specimen should be sent for smears, cultures, and 
histopathological examination. Corneal biopsy is considered to be 
superior to corneal scraping for the isolation of the fungal organisms. 
 
CALCOFLUOR WHITE: 
Calcofluor white has a sensitivity of 80 to 90 % in detecting the 
fungal pathogen. Excellent results can be achieved when the nonspecific 
fluorescent stain calcofluor white was used to stain corneal scrapes or 
biopsy specimens prior to direct microscopic examination. 
 
TREATMENT: 
MEDICAL THERAPY:[31-37] 
The development of new ocular antifungal agents have been 
hindered by the small market that fungal keratitis represents when 
compared with systemic fungal infections. With the exception of 
Natamycin, most of the antifungals used were developed for use in 
systemic mycoses. Before the advent of the first effective antifungal 
agents in the mid 1950’s, the medical treatment of fungal keratitis 
included methods such as sulphacetamide iontophoresis and thiomersal. 
Frequently, cauterisation and cryotherapy were used adjunctively. The 
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advent of the current antifungal medications has made a good impact on 
the management of the surface corneal infections. However, all the 
available antifungal agents are fungistatic and not fungicidal. The 
penetration of the drug is poor and has to be aided by repeated 
debridement, which acts by debulking of the pathogenic organism. The 
treatment schedules are often prolonged, often leading to poor 
compliance with medical therapy. Prompt and appropriate anti-fungal 
therapy is the mainstay of the treatment of fungal keratitis. Anti-fungal 
therapy should only be instituted where corneal scraping reveals the 
presence of fungal elements or cultures reveal the presence of fungal 
organisms at 36- 48 hours. Since the corneal epithelium serves as a 
barrier to the penetration of most tropical anti-fungal agents, debridement 
of the corneal epithelium is an essential component of the medical 
management of fungal keratitis. 
The antifungal medications can be broadly divided into: 
1. Polyenes 
2. Azoles 
3. Fluorinated pyrimidines 
4. Echinocandins 
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1. POLYENES: 
Polyenes constitute the first line of the antifungal agents. They bind 
preferentially to ergosterol in the fungal plasma membrane, thereby 
altering the membrane permeability and disrupting the fungal cell. Larger 
polyenes (such as Amphotericin B and Nystatin) create channels that span 
the cell membranes and allow electrolyte movement. Small polyenes such 
as Natamycin are too small to bridge the width of the cell membrane and 
causes localized membrane disruptions thus altering permeability. 
 
NATAMYCIN: 
Natamycin is a tetraene polyene and is the only antifungal 
commercially available in the United States in a topical ophthalmic form 
(Natacyn 5%, Alcon Laboratories). The agent was discovered in 1958, 
and it has proved itself to be the most valuable ocular antifungal agent. 
Available as 15 ml bottles, these containers may be stored at room 
temperature or refrigerated, but care should be taken to avoid freezing, 
exposure to light and high temperatures. Like other polyenes, it is 
insoluble in water. The commercial preparation is a suspension that must 
be shaken well before use. Natamycin often adheres to areas of corneal 
ulceration, perhaps increasing the duration of drug contact time. The drug 
cannot be administered systemically. Although the optimal dosing 
schedule for topical administration is not known, a loading dose approach 
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in which one drop is instilled into the conjunctival sac at half hour 
intervals appears appropriate initially. This rate can then be gradually 
reduced to one hourly drop 6-8 times daily after the first 3-4 days of 
administration. Natamycin has been considered to be poorly absorbed by 
the cornea. Fortunately, the relatively high total corneal drug 
concentration ensures that adequate amounts of bioactive drug are 
available. The corneal epithelium is a major barrier to corneal 
penetration. Removal of the epithelium dramatically enhances penetration 
and efficacy. 
 
EFFICACY AND SPECTRUM OF ACTIVITY: 
Natamycin is most effective against the filamentous fungi and has 
been of particular use in the treatment of Fusarium and Aspergillus 
infections, the commonest cause of fungal corneal ulcers around the 
world. However, treatment failures occur with this and other filamentous 
fungi. Numerous studies have established the primacy of natamycin in the 
treatment of fungal infections caused by filamentous fungi. 
 
AMPHOTERICIN B: 
Amphotericin B, a heptaene polyene, was the first polyene shown 
to be effective on treating systemic mycoses. Produced by Streptomycetes 
nodosus, it was identified in a soil culture from Venezuela in 1956 by 
Gold and colleagues. Amphotericin B is dispensed in 20 ml vials for 
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intravenous use containing 50 mg of amphotericin B powder, 41 mg of 
sodium deoxycholate and a sodium phosphate buffer. The powder is 
initially reconstituted to a concentration of 5mg/ml in 10 ml of sterile 
water for injection. For topical application, this solution is further diluted 
with sterile water to concentrations from 0.05% to 1%. Amphotericin B 
in solution should not be exposed to light. When stored at 36ºC, it retains 
potency for one week. The corneal epithelium appears to be a powerful 
barrier to corneal penetration of the drug. However, debridement of the 
epithelium greatly increases the penetration and efficacy. In the treatment 
of systemic mycoses, Amphotericin B is most efficacious against yeasts, 
particularly Candida and Cryptococcus sp. The agent is much less useful 
in filamentous fungal infections. It exerts antifungal activity against 
Aspergillus. In addition to its direct fungicidal activity, it has shown to 
have immunoadjuvant properties. The adverse effects of the topical 
application include stinging sensation on application, chemosis and 
punctuate epithelial keratitis. An initial dose of 0.15% is applied for every 
five minutes for half an hour as a loading dose and thereby hourly 
thereafter. Subconjunctival injections can cause conjunctival necrosis and 
should be avoided. Systemic administration of amphotericin B is nephro 
toxic and is ineffective in the treatment of fungal keratitis. 
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NYSTATIN: 
Nystatin is another polyene antifungal agent that is used as an 
ointment or formulated eye drops (50,000 units/ ml) and can be used for 
superficial Candidal keratitis. The ointment preparation causes severe 
stinging sensation and patient compliance is poor for prolonged usage. It 
is too toxic for parenteral administration. 
 
2. AZOLES: 
The azole group of antifungal agents have five-membered organic 
rings which contain either two or three nitrogen molecules (the 
imidazoles and the triazoles respectively). The imidazoles include 
clotrimazole, miconazole, econazole and ketoconazole. The triazoles 
include fluconazole and itraconazole. These drugs exhibit their antifungal 
acitivity by having two mechanisms of action.  
In lower concentration, they are fungistatic by inhibiting sterol 14 
alpha demethylase, a microsomal P-450 related enzyme, which is needed 
in the demethylation of lanosterol in the synthesis of ergosterol. At higher 
concentrations, they are fungicidal which is due to the direct membrane 
damage to the phospholipids present in the fungal cell wall. However 
they are never able to achieve fungicidal concentration in the human 
cornea. 
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ECONAZOLE: 
It is a dichlorimidazole and exhibits a wide spectrum of activity 
against filamentous fungi. A topical preparation of 1% econazole can be 
prepared and is well tolerated. 
 
KETOCONAZOLE: 
It inhibits ergosterol synthesis in vivo, thus damaging the fungal 
cell wall and altering the electrolyte concentration. The increased water 
solubility and enhanced systemic absorption are valuable properties of 
this drug. 
 
FLUCONAZOLE: 
A water soluble triazole is available in oral 100 mg capsules and 
intravenous solution. Although the minimal inhibitory concentrations of 
fluconazole are higher than other azoles in most susceptibility test 
systems, the in vivo activity of fluconazole does not parallel the efficacy 
in infections in animals and in clinical trials in humans. The 
recommended dose is 200- 40 mg/ day and is the same for oral and 
intravenous routes. It is useful in candida keratitis. 
 
ITRACONAZOLE: 
The newer oral triazole antifungal agent may also be helpful 
adjunctive agent in fungal keratitis. However it is quite hydrophobic, and 
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being 90% protein bound in the serum, it does not permeate the tissues as 
well as fluconazole. 
 
VORICONAZOLE: 
A new azole drug derived from fluconazole. Acts primarily 
through inhibition of cytochrome P450 dependent 14 alpha demethylase. 
This enzyme is responsible for the conversion of lanosterol to 14 alpha 
demethyl lanosterol. It has been shown  to have a broad spectrum of 
activity against Aspergillus, Candida, Paecilomyces, Cryptococcus, 
Scedosporium, Curvularia and others. It has excellent in vitro activity 
with low MIC values against Candida and Aspergillus species which are 
known to be resistant to amphotericin B, fluconazole and itraconazole. 
Activity against Fusarium species is variable. 
It has been also reported to be fungicidal against most Aspergillus 
species and some dematiaceous fungi. There is increasing trend of using 
topical, intrastromal, as well as oral routes in the treatment of fungal 
keratitis, and given its excellent penetration in the cornea, it is considered 
superior to natamycin by many authors. Studies have also reported the 
adjunctive therapy with natamycin in the face of no response to 
monotherapy to natamycin. Toxic effects include visual disturbances and 
skin rashes, which can be mild and transient. Elevations in hepatic 
enzymes can also occur. 
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POSACONAZOLE: 
Posaconazole is a second-generation triazole. It is primarily indicated 
for the treatment of invasive fungal infections in onco-hematological 
patients. It is only available as an oral solution and should be 
administered at a dose of 200 mg four times daily or 400 mg twice daily. 
Gastrointestinal complaints are the only adverse effects. In vitro and in 
vivo studies show its broad spectrum activity against Candida spp., 
Cryptococcus neoformans, Aspergillus spp., and Fusarium spp., among 
others. Experience with its use in ocular infections is still limited, but 
initial results are encouraging. In a series of three cases of Fusarium 
keratitis progressing to endophthalmitis unresponsive to treatment with 
oral and topical voriconazole, a rapid therapeutic response to 
posaconazole was observed. However, comparative controlled studies 
with first-line antifungal agents are still lacking. 
 
3. FLUORINATED PYRIMIDINES: 
FLUCYTOSINE: 
Fluocytosine (5- fluorocytosine) is a fluorinated pyrimidine. First 
synthesized in1957 as an antimetabolite in the treatment of leukemia, the 
antifungal properties of flucytosine were first described by Grunberg and 
colleagues in 1963. Flucytosine is transported across the fungal cell 
membrane by a specific permease elaborated by certain fungi. Once in the 
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cell, the agent is deaminated to fluororacil, a thymidine analogue that 
locks further fungal thymidine synthesis. Since mammalian cells do not 
normally metabolize flucytosine, it does not inhibit metabolic processes. 
The drug is well tolerated by the gastrointestinal tract. The therapeutic 
range can be achieved with the administration of a dose of 50- 150 
mg/kg/day in divided doses. A topical preparation can be made by 
dissolving the contents of a capsule of flucytosine in artificial tears. The 
solution should be filtered before use to remove any undissolved 
flucytosine. Flucytosine has been used with success as a 1% solution 
topically.  
 
4. ECHINOCANDINS:[36,37] 
 Echinocandins are semisynthetic lipopeptides. They inhibit the 
synthesis of glucan in the fungal cell wall through non-competitive 
inhibition of the enzyme 1,3-β-glucan synthase, causing osmotic 
imbalance and cell lysis. This class of drugs includes caspofungin and 
micafungin. Echinocandins have rapid fungicidal action against most 
Candida species. Echinocandins have fungistatic action against 
filamentous fungi such as Aspergillus, but not against Fusarium. 
Caspofungin is administered intravenously at a dose of 70 mg on the first 
day and 50 mg on the following days. Micafungin is also administered 
intravenously at a dose of 100 to 150 mg/day. Topical caspofungin at a 
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concentration 1.5 to 5 mg/ml was as effective as amphotericin B in the 
treatment of corneal ulcer by Candida albicans in an animal model.  
 
MODALITIES OF DRUG DELIVERY: 
TOPICAL THERAPY: 
The topical anti-fungal therapy is the mainstay of fungal keratitis. 
Commercially available natamycin 5% suspension is the initial drug of 
choice for fungal keratitis. It should be given hourly during the day and 
two hourly at bedtime. In addition to the anti-fungal drugs a broad-
spectrum antibiotic such as a fluoroquinolone may be given to prevent 
secondary bacterial infection. Additionally, cycloplegics such as 
homatropine eye drops may be given three times a day to relieve the 
component of iridocyclitis along with the anti-glaucoma medications in 
cases where the intraocular pressure is high on digital tonometry. The eye 
should be examined twice daily preferably under the slit lamp. Once the 
infiltrate started resolving, the frequency of topical natamycin is reduced 
to 2-hourly until the completion of resolution. The natamycin should be 
continued for 2 weeks after the resolution of infection in all cases. If 
worsening of the keratitis is observed on topical natamycin, topical 
amphotericin B 0.15% or topical voriconazole 1% may be added as a 
second agent. Amphotericin B is not effective against Fusarium species. 
The efficacy of Econazole 1% against filamentous fungi has been found 
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to be equivalent to natamycin 5%. The imidazoles (ketoconazole and 
miconazole) are used systemically for the treatment of keratomycosis 
because of their relatively reduced systemic toxicity. 
 
INTRACAMERAL THERAPY: 
Intracameral amphotericin B may be a useful modality in the 
treatment of severe keratomycosis not responding to topical natamycin. It 
ensures adequate drug delivery into the anterior chamber and may be 
especially useful to avoid surgical intervention in the acute stage of the 
disease. The procedure should be performed under strict aseptic 
conditions. If the infection involves the anterior capsule of the lens, care 
should be taken to avoid injury to the lens. Patients with deep 
keratomycosis unresponsive to conventional medical treatment are 
candidates for intracameral injections of 5 μg Amphotericin B in 0.1 ml 
5% dextrose. Injections can be repeated in case of inadequate response. 
 
INTRACORNEAL THERAPY: 
A recent modality advocated for non healing fungal corneal ulcers 
is the use of intracorneal antifungal injections. They can be given as an 
intrastromal injection at the junction of clear cornea and infiltrates, using 
a 30-gauge needle in five quadrants to form a barrage around the ulcer. 
This would raise the local concentration of the antifungal agent enough to 
be effective in the eradication of the deep corneal infection. Amphotericin 
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B in 5-7.5 μg dosage or voriconazole in 50 mg in 0.1 ml can be injected. 
Various studies have shown that intrastromal voriconazole may be used 
as a modality of treatment for recalcitrant fungal keratitis. 
 
RESPONSE TO THERAPY: 
Since fungal keratitis responds slowly over a period of weeks, 
clinical signs of improvement should be noted which include the 
following: diminution of pain, decrease in size of infiltrate, disappearance 
of satellite lesions, rounding out of the feathery margins of the ulcer. 
 
DURATION OF TREATMENT: 
In general the duration of treatment is longer than that for cases of 
bacterial keratitis. The clinician must determine the length of treatment 
for each individual based on clinical response. The duration of the 
treatment for topical treatment has not been firmly established clinically 
or experimentally and varies from 30 to 39 days. Problems that can rise 
from prolonged treatment are due to toxicity. The inflammatory response 
from this toxicity can be confused with persistent infection. If toxicity is 
suspected and if adequate treatment has been given for at least 4 to 6 
weeks, treatment should be discontinued and the patient carefully 
observed for evidence of recurrence. 
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DRUG INTERACTIONS: 
Several topical anti-fungal medications act synergistically against a 
particular fungal organism. In clinical series more than one concurrent 
topical anti-fungal has been needed 5% of the time. Synergistic drugs 
include a combination of amphotericin B and flucytosine, (for Candida 
keratitis) and a combination of natamycin and ketoconazole (for 
Aspergillus keratitis). Likewise, experimental models have demonstrated 
the potential antagonism between anti-fungals such as amphotericin B 
and the imidazoles. 
 
DRUG RESISTANCE: 
Resistance to anti-fungal agents is rare and generally occurs when 
they are used for systemic mycoses. Competition for volume in the pre 
corneal tear film and washout may be of more concern when using two 
topical antifungals. 
 
SYSTEMIC THERAPY: 
The use of systemic anti-fungal agents is generally not indicated in 
the management of fungal keratitis. Treatment with a systemic anti-fungal 
agent is recommended in cases of very large ulcers, severe deep keratitis, 
scleritis and endophthalmitis. Systemic anti-fungals also may be used as 
prophylactic treatment after penetrating keratoplasty for fungal keratitis. 
The drugs, which have been used systemically, include ketoconazole, 
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itraconazole and fluconazole. The most frequently used oral anti-fungal is 
ketoconazole, which is given in the dose of 600 mg per day. It is 
mandatory to assess liver function tests every 2 weeks after starting 
ketoconazole. 
 
SURGICAL THERAPY:[38-43] 
 
DEBRIDEMENT: 
Daily debridement with a spatula or blade is the simplest form of 
surgical intervention and is usually performed at the slit lamp under 
topical anaesthesia. Debridement is performed every 24 to 48 hours and 
works by debulking organisms and necrotic material and by enhancing 
the penetration of the topical antifungal. 
 
THERAPEUTIC KERATOPLASTY: 
Approximately one third of fungal infections result in either 
medical treatment failures or corneal perforations. The main goals are to 
control the infection and maintain the integrity of the globe. Most 
retrospective series indicate that keratoplasty was performed within 4 
weeks of presentation, primarily because of medical treatment failures; in 
some cases it may be required because of recurrence of infection. When 
progression of the keratitis is noted, penetrating keratoplasty should be 
performed. If the infectious process is allowed to progress until it 
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involves the limbus or sclera, unfavourable outcomes secondary to 
scleritis, endophthalmitis, and recurrence are more common. Therapeutic 
keratoplasty should be performed in cases of impending perforations, 
frank perforations > 2mm or if there is no response to therapy. The 
technique of the keratoplasty is similar to that performed for other forms 
of microbial keratitis. The size of the trephination should leave a 1 to 
1.5mm clear zone of clinically uninvolved cornea to reduce the 
possibility of residual fungal organisms peripheral to the trephination. 5 
Interrupted sutures with slightly longer bites should be used to avoid 
cheese wiring of the suture if the edge of the recipient becomes involved 
with a persistent organism. Irrigation of the anterior segment should be 
performed to eliminate any organisms. As far as possible the lens should 
be left untouched to prevent the spread of infection in the posterior 
segment. However, if affected the intraocular structures including the iris, 
lens, and vitreous may be excised. The specimens removed should be 
submitted to both the microbiology and pathology laboratories for culture 
and fixed section examination. If involvement of intraocular structures or 
endophthalmitis is suspected, an antifungal agent should be injected 
which includes amphotericin B (5μg/0.1ml) or miconazole (25μg/ 
25μg/0.1ml). It is mandatory to submit surgical specimens from cases of 
microbial keratitis for histopathologic examination especially if the 
microbiologic diagnosis is not known. Histopathologic examination of 
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corneal buttons can reveal the presence of fungal elements in 75% 
patients. It has been shown that 59% of corneas infected by fungi are still 
culture-positive at the time of keratoplasty, with 90% of eyes exhibiting 
hyphal elements on pathologic examination. Fungal hyphae usually lie 
parallel to the corneal surface and lamellae. A vertical or perpendicular 
arrangement of fungal hyphae in the corneal stroma has been associated 
with increased virulence and in patients on topical corticosteroid therapy. 
Descemet’s membrane may function as a barrier for invasion of 
microorganisms. Fungi have been shown to penetrate through an intact 
Descemet’s membrane. After penetrating keratoplasty, topical antifungal 
agents should be continued to prevent recurrence of infection. 
Postoperatively, systemic keatoconazole or fluconazole may be used in 
addition to topical anti-fungal agents. If the pathology laboratory reports 
that no organisms were seen at the edge of the corneal specimen, 
antifungals could be stopped after 2 weeks and the patient followed 
carefully for recurrences. A report from the microbiology laboratory 
regarding growth of organisms from the corneal or intraocular tissues 
should indicate the need for more prolonged topical and systemic anti-
fungal therapy, possibly for 6 to 8 weeks. The use of topical 
corticosteroids in the postoperative management of fungal keratitis is 
controversial. At the time of keratoplasty, if the infection has been 
controlled clinically, topical corticosteroids may be used. If it is not 
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known whether the infection is controlled, corticosteroids should be 
avoided during the early postoperative period. Although the main goal of 
penetrating keratoplasty in fungal keratitis is to eliminate the infecting 
organism, a secondary goal is the maintenance of a clear corneal 
transplant for optical reasons. Even if graft failure or rejection occurs, the 
patient can undergo a second optical keratoplasty once the rejection is 
controlled.  
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REVIEW OF LITERATURE: 
Review of literature was done using PubMed search. 
 
Whitcher et al [1]: Ocular trauma and corneal ulceration are 
significant causes of corneal blindness and are responsible for 1.5–2.0 
million new cases of monocular blindness every year. 
 
Srinivasan et al [2]: A prospective study of 434 patient with central 
corneal ulceration were evaluated. A history of previous corneal injury 
was present in 65.4% of patients. Cornea cultures were positive in 68.4%. 
Of those individuals with positive cultures 46.8% had pure fungal 
infections. The most common fungal pathogen isolated was Fusarium 
spp, representing 47.1% of all positive fungal cultures, followed by 
Aspergillus spp (16.1%). 
 
Leck et al [3]: A multicenter study done in Ghana and southern 
India evaluated 1090 patients with suspected microbial keratitis. Overall 
the principal causative micro-organisms in both regions were filamentous 
fungi (42%). Fusarium species and Aspergillus species were the 
commonest fungal organisms isolated. 
 
Prajna et al [4]: The mycotic ulcer treatment trial, which was a 
randomized trial comparing natamycin and  voriconazole. A total of 940 
patients were screened and 323 were recruited in the trial. Causative 
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organisms included Fusarium (128 patients [40%]), Aspergillus (54 
patients [17%]), and other filamentous fungi (141 patients [43%]). Those 
cases treated with natamycin had significantly better 3-month best 
spectacle-corrected visual acuity than voriconazole treated cases 
(regression coefficient=0.18 logMAR; 95% CI, 0.30 to 0.05; P=.006). 
The group on treatment with natamycin were less likely to have 
perforation or require therapeutic penetrating keratoplasty (odds 
ratio=0.42; 95% CI, 0.22 to 0.80; P=.009). Fusarium cases fared better 
with natamycin than with voriconazole (regression coefficient=0.41 
logMAR; 95% CI,0.61 to 0.20; P<.001; odds ratio for perforation=0.06; 
95% CI, 0.01 to 0.28; P<.001), while non-Fusarium cases fared similarly 
(regression coefficient=0.02 logMAR; 95% CI, 0.17 to 0.13; P=.81; odds 
ratio for perforation=1.08; 95% CI, 0.48 to 2.43; P=.86). The study 
concluded that treatment with natamycin was associated with 
significantly better clinical and microbiological outcomes than those 
treated with voriconazole for smear-positive filamentous fungal keratitis, 
with much of the difference attributable to improved results in Fusarium 
cases. 
 
Prajna et al [5]: A multicenter, double-masked, clinical trial which 
included 120 patients with fungal keratitis were randomized to receive 
either topical natamycin or topical voriconazole. Upon comparison 
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between the two groups, voriconazole-treated patients had an 
approximately 1-line improvement in BSCVA at 3 months after adjusting 
for scraping in a multivariate regression model but the difference was not 
statistically significant (P=.29). Scar size at 3 months was slightly greater 
with voriconazole after adjusting for scraping (P=.48). Corneal 
perforations in both the groups were not significantly different (P>.99). 
Scraping was associated with worse BSCVA at 3 months (P=.06). 
Patients with the baseline BSCVA of 20/40 to20/400 showed a trend 
toward a 2-line improvement in visual acuity with voriconazole (P=.07). 
However, there was no significant difference in visual acuity, scar size, 
and perforation between voriconazole and natamycin treated patients. 
 
Prajna et al [6]: A randomized clinical trial comparing 2% 
econazole and 5% natamycin for the treatment of fungal keratitis. There 
were no significant differences between the two groups at baseline or for 
success (defined as a healed or healing ulcer) at final visit (p = 0.79) and 
thus 2% Econazole appeared to be as effective as 5% natamycin for the 
treatment of mycotic keratitis. 
 
Xie et al [7]: Fungal keratitis constituted 61.9% of cases of severe 
infective keratitis in north China. Males (60.6%) were more likely to be 
affected than females (39.4%). Corneal trauma (51.4%), especially injury 
from plants (25.7% in all patients), was the most commonly associated 
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risk factor. Direct microscopic examination of the corneal scraping 
samples after staining with potassium hydroxide showed positivity in 
88.7% of the eyes. The fungal isolates found were of Fusarium species in 
437 eyes (73.3%) and Aspergillus species in 72 eyes (12.1%). Surgical 
interventions were performed in 604 eyes (92.4%), including therapeutic 
penetrating keratoplasty in 399 eyes (66.0%) and therapeutic lamellar 
keratoplasty (LK) in 177 eyes (29.3%). 
 
Prajna et al [8] compared results of 47 subjects on concurrent use of 
5% natamycin and 2% econazole. Baseline characteristics were similar 
between the 2 groups. There were no significant differences (P = 0.9) 
between the two groups for success (defined as a healed or healing ulcer). 
Concurrent use of 5% natamycin and 2% econazole did not have 
additional benefits over monotherapy with 5% natamycin for the 
management of fungal keratitis. 
 
Miedziak et al [9]: Old age (P=0.001), delay in referral to the 
corneal specialist (P<0.03), and treatment with topical steroids prior to 
initial presentation (P<0.0001) were statistically significant factors 
associated with the need for penetrating keratoplasty. A past history of 
ocular surgery (P=0.01), poor visual acuity at presentation (P<0.001), 
central location of ulcer(P<0.0001), large size of ulcer (P<0.0001), 
presence of perforation or descemetocele (P<0.0001), involvement of 
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limbus (P<0.0001), and presence of hypopyon (P=0.05), were all 
associated with the need for penetrating keratoplasty. 
 
Anuradha et al [10]: A prospective hospital-based study. Mycotic 
keratitis was diagnosed in 191 (39%) out of the total study population of 
485 cases. Direct microscopic examination of KOH mounts and Gram-
stained smears revealed presence of fungal elements in the corneal 
scrapings in 119 (62.3%) and114 (60%) of the subsequently fungal 
culture-positive cases, respectively. Men (68%) were more commonly 
affected than women (32%). Young adults 31–40 years of age were the 
most common age group to be involved (36%). Multiple predisposing 
risk factors were noted in 79%, with corneal trauma 42%, contact lens 
wear 25%,and topical corticosteroids in 21% patients. The spectrum of 
fungi isolated were Aspergillus species in 78 (41%) followed by 
Curvularia species in 55 (29%), in contrast to other studies from Southern 
India. 
 
Lalitha et al [11]: A prospective study to characterize the 
antimicrobial susceptibility of filamentous fungi. The 90 fungal isolates 
included 41 Aspergillus species,38 Fusarium species, and 11 others. The 
triazoles and caspofungin had the lowest MICs against Aspergillus 
species; voriconazole, amphotericin B, and posaconazole had the lowest 
MICs against Fusarium species, and none of the Fusarium species were 
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inhibited by itraconazole or caspofungin. Amphotericin B had 
significantly lower MICs compared with natamycin, but after correcting 
for the typical prescription dose, natamycin was superior. In conclusion 
no single agent was universally most effective, but voriconazole and 
other triazoles demonstrated the broadest spectrum. Itraconazole and 
caspofungin were not effective against Fusarium species. 
 
Jurkunas et al [12]: A detailed study on demographics and pathogens 
for fungal keratitis cases diagnosed at the Massachusetts Eye and Ear 
Infirmary. During 2004–2007, the rate of fungal keratitis was 1.0 cases 
per month, an increase from the baseline rate of 0.5 cases per month 
during 1999–2002. The proportion of cases caused by filamentous fungi 
increased from 30% (1999–2002) to 65% (2004–2007) (P = 0.01). Soft 
contact lens wear accounted for 41% of fungal keratitis cases in 2004–
2007, as compared with 17% in 1999–2002.The majority of patients 
(70%) received oral antifungal treatment in addition to topical 
amphotericin B and natamycin. Seventeen patients (40%) required 
therapeutic keratoplasty. Patients with a history of corneal transplant had 
the highest rate of therapeutic keratoplasties (67%) and had the poorest 
visual outcome (40% counting fingers or less). In the contact lens group, 
94% of patient maintained vision of at least 20/40 and only 12% required 
surgery to control the infection.  
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Bharathi et al [13] reported a large series of fungal ulcers (1095) 
occurring in South India. This retrospective study involved 3183 patients 
with corneal ulcer in a 3-year period from a single tertiary eye care 
center. Out of 3183 patients, 1095 (34.4%) had fungal keratitis. The 
Fusarium species was the principal pathogen (42.82%) Male patients 
were commonly affected (65%). Most of them (66.85%) were in the 
younger age group (21–50 years).Fungal keratitis patients had 
experienced ocular trauma (92%) and vegetable injury (61%). The 
sensitivity of KOH was 99%. 
 
Sengupta et al [14]: A retrospective study on 3059 cases of 
presumed microbial keratitis, 1756 had positive cultures (57.4%). Among 
the culture-positive cases, fungal pathogens were isolated from 1224 
cases (70%), 488 (27.7%) showed bacterial growth, 18 (1.03%) grew 
acanthamoeba species and 26 (1.5%) demonstrated mixed bacterial and 
fungal growth. The percentage of fungal isolates in culture-positive cases 
increased gradually over the study period from 59% in 2004 to 78% in 
2009. This increase in frequency of fungal keratitis was statistically 
significant (P = 0.023). A proportionally decreasing trend was seen in the 
number of bacterial isolates ranging from 31% in 2003–2005 to 22% in 
2009 (P = 0.04). 
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Lalitha et al [15] described the minimum inhibitory concentration 
(MIC) of fungal isolates to natamycin and voriconazole. Of the 323 
patients, MICs were available for 221 (68%). Fusarium (N=126) and 
Aspergillus species (N=52) were the most commonly isolated organisms. 
MICs to natamycin and voriconazole were significantly different across 
all genera (P<0.001). The MIC median (MIC50) and 90th percentile 
(MIC90) for natamycin were equal to or higher than voriconazole for all 
organisms, except Curvularia species. Compared to other organisms, 
Fusarium species isolates had the highest MICs to voriconazole and A. 
flavus isolates had the highest MICs to natamycin. These results were 
similar to previous reports except that the voriconazole MIC90 against 
Aspergillus species was 2-fold higher and the natamycin MIC90 against 
A.fumigatus was 4-fold higher. Fusarium isolates were least susceptible 
to voriconazole and A. flavus isolates were least susceptible to natamycin 
when compared to other filamentous fungi. 
 
Gupta et al [16]: This was a clinico-demographical study done in 
North India and 209 cases of keratitis were studied, culture yielded 
growth in 80 cases (38.3%). Out of these 80 cases of growth, fungi were 
isolated in 77.5% and bacteria in 22.5%. The spectrum of keratomycosis 
was Aspergillus flavus (22.5%), Fusarium solani (16.1%), A. fumigatus 
(11.3%), Candida albicans (6.4%). 
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Basak et al [17] reported the epidemiologcial pattern and risk factors 
involved in suppurative corneal ulceration in eastern India. Over a three-
year period, 1198 patients with suppurative keratitis were evaluated. 
Ocular trauma was the most common predisposing factor in 994 (82.9%) 
patients (P<0.0001), followed by use of topical corticosteroids in 231 
(19.28%) patients. Cultures were positive in 811 (67.7%) patients. 
Among these culture positive cases, 509 (62.7%) patients had pure fungal 
infections (P<0.001), 184 (22.7%)patients had pure bacterial infections 
and 114 (14.1%) had mixed fungal with bacterial infections. 
Acanthamoeba was detected in 4 (0.49%) patients. The most common 
fungal pathogen was Aspergillus spp representing 373 (59.8%) of all 
positive fungal cultures (P<0.0001), followed by Fusarium spp in 132 
(21.2%) instances. 
 
Sun et al [18] assessed the association between minimum inhibitory 
concentration (MIC) and clinical outcomes in a fungal keratitis clinical 
trial. A 2-fold increase in MIC was associated with a larger 3-month 
infiltrate/scar size (0.21mm, 95% confidence interval [CI] 0.10–0.31, P 
<0.001) and increased odds of perforation (odds ratio [OR] 1.32, 95% CI 
1.04–1.69, P=0.02). No correlation was found between MIC and 3-
monthvisual acuity. For natamycin-treated cases, an association was 
found between higher natamycin MIC with larger 3-month infiltrate/scar 
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size (0.29 mm, 95% CI 0.15–0.43, P<0.001) and increased perforations 
(OR 2.41, 95% CI 1.46–3.97, P<0.001). Among voriconazole-treated 
cases, the voriconazole MIC did not correlate with any of the measured 
outcomes in the study. This study concluded that decreased susceptibility 
to natamycin was associated with increased infiltrate/scar size and 
increased odds of perforation and there was no association between 
susceptibility to voriconazole and outcome. 
 
Sharma et al [19] assessed the outcomes of therapeutic penetrating 
keratoplasty from a tertiary eye care centre in northern India. In this 
retrospective interventional study, a cohort of 506 eyes that underwent a 
TPK for microbial keratitis was evaluated. TPK was performed in cases 
of recalcitrant microbial keratitis with impending perforation 
(descemetocele formation) or perforation (>3 mm). Anatomical success 
was seen in 454 eyes (89.7%). Preoperatively, the corrected distance 
visual acuity was <3/60 in 495 eyes (97.8%); after performing the TPK, 
the corrected distance visual acuity was <3/60 in 249 eyes (49.2%), 3/60 
to 6/60 in 182 eyes (35.9%), and >6/60 in 75 eyes (14.8%). Eyes with 
smaller grafts (<9 mm) had better anatomical and visual outcomes 
compared with eyes with larger grafts (9-11 mm; P = 0.03 and >11 mm; P 
= 0.0). A higher success rate was achieved with pure bacterial 
or fungal organisms rather than with mixed infections. A higher incidence 
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of secondary glaucoma was seen in eyes with perforated ulcers (29.36%; 
111/378) than in eyes without perforation (11.71%; 15/128) (P <.01) and 
in eyes with larger graft sizes (>11 mm and 9-11 mm) than in eyes with 
smaller graft sizes (<9 mm) (P <0.01). 
 
Sharma et al [20] compared the efficacy of topical voriconazole and 
topical natamycin with that of intrastromal voriconazole and topical 
natamycin in patients with recalcitrant fungal keratitis. The patients in 
both groups had comparable baseline parameters. The mean BSCVA after 
treatment was 1.295 ± 0.5 logarithm of the minimum angle of resolution 
(logMAR) units in the topical group and 1.692 ± 0.29 logMAR units in 
the intrastromal group. The visual acuity after treatment was significantly 
better in the topical voriconazole group (P = 0.008). Nineteen patients 
receiving topical voriconazole and 16 patients who were given 
intrastromal voriconazole healed with therapy. Topical voriconazole 
seems to be a useful adjunct to natamycin in fungal keratitis not 
responding to topical natamycin. However intrastromal injections do not 
offer any beneficial effect over topical therapy. 
 
 
 
 
 
 
 
 
 
 
PART II 
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AIM: 
To compare the treatment outcomes following Fusarium and 
Aspergillus keratitis in a tertiary eye care centre.  
 
OBJECTIVES: 
PRIMARY: 
1. Best corrected visual acuity (BCVA) at 3 months from enrollment. 
 
SECONDARY: 
1. Time to re-epithelialization. 
2. Scar size at 3 months from enrollment. 
3. Ulcers healed with monotherapy (Natamycin).  
4. Incidence of corneal perforation or need for therapeutic penetrating 
keratoplasty (TPK). 
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STUDY DESIGN: 
- It is a hospital based prospective, non randomized, observational 
clinical study. 
 
PLACE OF STUDY: 
- The study was conducted in the department of Cornea, Aravind Eye 
Hospital and Post Graduate Institute of Ophthalmology, Madurai, 
Tamil Nadu. 
 
STUDY POPULATION:  
- Patients with fungal corneal ulcers which are culture positive for 
Fusarium or Aspergillus species. 
 
SAMPLING TECHNIQUE: 
- Non probable convenient sampling  
 
SAMPLE SIZE: 
- All culture proven Fusarium and Aspergillus fungal keratitis cases 
presenting to the cornea department during the study period.  
 
DURATION OF THE STUDY: 
- Study period: 01/12/2015 to 28/02/2017. 
(Inclusive of a follow up period of 3 months) 
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INCLUSION CRITERIA: 
1. Presence of corneal ulcer at presentation (defined by an epithelial 
defect and stromal inflammation) 
2. Fusarium or Aspergillus species identified on culture media. 
3. Ulcer area of at least 2 mm2. 
4. The patient must have a basic understanding of the study and to 
return for follow- up visits.  
5. Appropriate consent 
 
EXCLUSION CRITERIA: 
1. Impending perforation at presentation. 
2. Perforation at presentation. 
3. Ulcer area greater than 60 mm2. 
4. Evidence of mixed infection (bacteria) on Gram stain. 
5. Evidence of Acanthamoeba keratitis. 
6. Evidence of herpetic keratitis. 
7. Age <16 years 
8. Bilateral ulcers 
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METHOD: 
This is a hospital based, prospective, observational study. The 
patients for this study were recruited from the department of Cornea, 
Aravind Eye Hospital, Madurai. Each patient with keratitis who presented 
to the department had a clinical examination using a slit lamp 
biomicroscope to measure size and depth of ulceration following a 
detailed clinical and demographic history. The visual acuity was checked 
using Snellen’s chart at 6 meters. A calibrated slitlamp biomicroscope 
was used to assess the size of the infiltrate or scar, epithelial defect, depth, 
hypopyon, and ocular adverse events at enrollment, 3 weeks from 
enrollment and 3 months from enrollment. Infiltrate or scar size and 
epithelial defect size were measured in a protocol identical to the Steroids 
for Corneal Ulcers Trial by measuring the longest dimension and the 
longest perpendicular, a protocol adapted from the Herpetic Eye Disease 
Study. As in the Steroids for Corneal Ulcers Trial, re- epithelialization 
was defined as the absence of an epithelial defect with the administration 
of fluorescein.  
 
The site of the ulcer was defined as either being entirely in the 
periphery or overlapping the central 4-mm circle and periphery without 
filling the centre or entirely in the central 4-mm circle or entirely filling 
the 4-mm circle and extending to the periphery. The depth was assessed 
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in 3 categories: more than 0% to 33%; more than 33% to 67%; and more 
than 67% to 100%. Lacrimal duct syringing and random blood sugar level 
measurement were additionally done for all patients. 
 
MICROBIOLOGICAL METHODS: 
The corneal scrapings were obtained after determination of 
baseline visual acuity and slitlamp examination and after administration 
of topical anesthetic agent (tetracaine hydrochloride, 0.5%, or lidocaine 
hydrochloride, 4%). Under magnification, a flame-sterilized Kimura 
spatula was used to obtain a scrape from the leading edge and base of the 
corneal ulcer. Two scrapings were smeared directly on separate glass 
slides for Gram staining and 10% potassium hydroxide wet mount. 
Subsequent scrapings were directly inoculated onto blood agar and potato 
dextrose agar for bacterial and fungal cultures. 
Fungal smears were considered positive when fungal elements 
were seen under low-power magnification and reduced light. Fungal 
cultures were considered positive with growth on any 2 media or 
moderate to heavy growth on 1 medium. Patients with proved fungal 
keratitis (smear and culture positive for fungus) with an ulcer area of at 
least 2 mm2 and not more than 60 mm2 were identified as potential 
participants for the study. Patients who were not willing to be part of the 
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study, and who did not meet the inclusion criteria were excluded from the 
study. 
Depending upon the presenting features the patients were started 
on topical anti fungal medications, either topical 5% Natamycin 
suspension eye drops as monotherapy or in combination with either 1% 
Voriconazole eye drops or 1% Itraconazole eye ointment. Additionally, 
1% atropine sulphate ointment was applied three times per day in the 
affected eye at least 15 minutes after the application of the antifungal eye 
drops. Additionally, details of signs including lid oedema, congestion of 
the conjunctiva, and hypopyon were recorded for each pateint. The 
presence or absence of hypopyon in the anterior chamber was noted, and 
quantified in millimetres. The patients were followed up regularly with a 
constant emphasis on 3 weeks and 3 month follow up periods, measuring 
the size and depth of the infiltrate. 
The primary outcome was best spectacle-corrected visual acuity 
(BSCVA) 3 months from enrollment. Secondary outcomes included scar 
size at 3 months, time to re- epithelialisation, the incidence of ulcers 
healed with monotherapy (Natamycin) and the incidence of corneal 
perforation and/or the need for therapeutic penetrating keratoplasty 
(TPK). 
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END POINT: 
1. HEALED: 
We defined a healed corneal ulcer as a completely healed epithelial 
defect with no stain on fluorescein application, and non-progression of 
the stromal infiltration.  
 
2. HEALING: 
A corneal ulcer was considered to be healing if the epithelial defect 
decreased in size by at least 20%, with non-progression or decrease in the 
size of the stromal infiltration by at least 20%.  
 
3. REMAINED SAME: 
A corneal ulcer was considered to remain the same if the size and 
depth of the infiltrate remained the same after initiation of treatment.  
 
4. WORSENED: 
An ulcer was considered to have worsened if the size and depth of 
the ulcer increased by at least 20%, or if the ulcer perforated. 
End points 1 and 2 were considered as effective treatment while 
end points 3 and 4 were considered as non effective treatment. 
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DATA COLLECTION TECHNIQUE AND TOOLS: 
 All the data from the primary source was collected by an individual 
interview, observation and complete ophthalmic examination of the 
subjects as per the preset proforma and any additional information like 
complications and its management was mentioned in detail. Later these 
primary data was entered in a Microsoft Excel sheet for a complete 
database. Data was also collected from secondary sources like Pubmed, 
Medline, Cochrane and various journals for comparison with the primary 
data. 
 
STATISTICAL METHODS: 
 Mean (SD) or Frequency (Percentage) was used for continuous and 
categorical variables respectively.  
 Student’s t-test or Mann- Whitney U test was used to assess the 
difference between the continuous variables.   
 Fisher’s exact test or chi-square test was used to assess the 
difference between the categorical variables.   
 P-value of less than 0.05 was considered as statistically significant.   
 Microsoft Excel sheet was used as a database tool. 
 All statistical analysis was done by statistical software STATA 
11.0 (Texas, USA). 
 
 
 
 
 
 
 
 
 
 
CLINICAL PHOTOS OF FUNGAL 
CORNEAL ULCERS 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1: FEATHERY MARGINS 
 
 
 
FIGURE 2: SATELLITE LESIONS 
 
 
FIGURE 3: HYPOPYON 
 
 
 
FIGURE 4: ENDOTHELIAL PLAQUE 
 
 
FIGURE 5: PERFORATION 
 
 
FIGURE 6: PERFORATION, AFTER FLUORESCEIN STAINING 
 
FIGURE 7: ULCER WITH LIMBAL INVOLVEMENT 
 
 
FIGURE 8: POST THERAPEUTIC PENETRATING 
KERATOPLASTY 
 
FIGURE 9: HEALED FUNGAL ULCER 
 
FIGURE 10: HEALED FUNGAL ULCER, AFTER FLUORESCEIN 
STAINING 
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RESULTS: 
 A total of 404 eyes of 404 patients were included in the study as 
per study protocol to compare the treatment outcomes following 
Fusarium and Aspergillus keratitis. This is a prospective study done at 
Aravind Eye Hospital, Madurai. Demographic profile of the patients 
included in the study is   summarized below. 
 
DEMOGRAPHIC CHARACTERISTICS: 
AGE DISTRIBUTION: 
 The average age at presentation was 50.23 ± 9.95 years (1SD), 
minimum being 20 years and maximum being 70 years. A maximum 
number of 176 patients (43.56%) were between 51 to 60 years. 
 
TABLE NO: 1 
AGE IN 
YEARS 
n Mean (SD) Min - Max 
404 50.23 (9.95) 20 - 70 
 
TABLE NO: 2 
AGE GROUP n (%) 
20 to 30 years 24 (5.94) 
31 to 40 years 39 (9.65) 
41 to 50 years 124 (30.69) 
51 to 60 years 176 (43.56) 
61 to 70 years 41 (10.15) 
Total 404 (100) 
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GRAPH NO: 1 
 
 
 
GENDER DISTRIBUTION: 
 Among the 404 patients in the study, 254 (62.87%) were males and 
150 (37.13%) were females. This showed that there was a male 
preponderance. 
TABLE NO: 3 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER n (%) 
Male 254 (62.87) 
Female 150 (37.13) 
Total 404 (100) 
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GRAPH NO: 2 
 
 
 
OCCUPATION DISTRIBUTION: 
 The occupational status of the 404 patients is shown in table No. 4. 
Of these, a majority of 264 (65.35%) patients were involved in 
agricultural work/ farming. 
TABLE NO: 4 
 
OCCUPATION n (%) 
Agricultural worker/farmer 264 (65.35) 
Labourer* 85 (21.04) 
Tradesman/profession€ 38 (9.41) 
Unemployed 17 (4.21) 
Total 404 (100) 
 
*An individual who does heavy manual labour, lifting, loading, 
and carrying of materials usually balanced on the head. 
€Includes mechanics, stone masons, electricians and welders. Also 
includes professions such as police, office workers, factory 
workers and drivers. 
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AGENT CAUSING TRAUMA: 
 A recent history of injury to the affected eye was present in 178 
(44.06%) eyes. The most common agent causing trauma was found to be 
vegetable matter in 63 (35.39%) eyes, followed by thorn or tree branch in 
43 (24.16%) eyes and with animal matter in 35 (19.66%) eyes. 
 
TABLE NO: 5 
MODE OF TRAUMA n (%) 
Vegetable matter 63 (35.39) 
Thorn or tree branch 43 (24.16) 
Animal matter£ 35 (19.66) 
Dust 18 (10.11) 
Fingernail 13 (7.30) 
Others 6 (3.37) 
Total 178 (100) 
    £Cow’s tail, cow dung, insect. 
 
 
59 
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Out of the 264 patients employed in agricultural work/ farming, 
114 (43.18%) patients had a history of trauma to the affected eye. 
 
TABLE NO: 6 
 
OCCUPATION 
TRAUMA 
P value c Yes 
n (%) 
No 
n (%) 
Total 
n (%) 
Agricultural 
worker/farmer 114 (43.18) 150 (56.82) 264 (100) 
0.646 
Labourer 38 (44.71) 47 (55.29) 85 (100) 
Tradesman/profession 16 (42.11) 22 (57.89) 38 (100) 
Unemployed 10 (58.82) 7 (41.18) 17 (100) 
Total 178 (44.06) 226 (55.94) 404 
C – Chi square test 
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SYSTEMIC DISEASE ASSOCIATION: 
 Of the 404 patients, 127 (31.44%) patients had an underlying 
systemic disease, amongst which 86 (67.72%) patients were diabetics. 
 
GRAPH NO: 5 
 
 
PRIOR NATIVE TREATMENT: 
Inappropriate native medications were applied in 42 (10.40%) eyes 
prior to presentation, mostly being mother’s milk application in 18 
(4.46%) eyes. 
TABLE NO: 7 
RECENT NATIVE 
MEDICATIONS 
n (%) 
Mother’s milk 18 (4.46) 
Oil¥ 8 (1.98) 
Chicken blood 6 (1.48) 
Tongue 10 (2.48) 
Nil 362 (89.60) 
Total 404 (100) 
  ¥ castor oil/ seed oil 
61 
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PRIOR MEDICATION USAGE: 
Preceding their initial visit to our hospital, 340 (84.16%) patients 
had applied topical medications in the form of antifungal, antibacterial 
and/or steroids, either alone or in combination. 
 
GRAPH NO: 7 
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MICROBIOLOGICAL FINDINGS: 
 Among the 404 patients in the study, 234 (57.92%) patients had 
positive culture for Fusasium species and 170 (42.08%) patients were 
found to be culture positive for Aspergillus species. 
 
TABLE NO: 8 
 
CULTURE n (%) 
Fusarium 234 (57.92) 
Aspergillus 170 (42.08) 
Total 404 (100) 
 
GRAPH NO: 8 
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CLINICAL CHARACTERISTICS: 
VISUAL ACUITY: 
 The visual acuity at presentation of all 404 patients were analysed, 
the results are given below. The values ranged between 0.18 to 2.9 
logarithm of the minimum angle of resolution (logMAR) units with a 
mean value of logMAR 1.09 ± 0.67 (1SD) units. 
 
TABLE NO: 9 
VISUAL 
ACUITY 
(logMAR) 
n Mean (SD) Min – Max 
Initial VA 404 1.09 (0.67) 0.18 – 2.9 
 
ULCER CHARACTERISTICS: 
ULCER SIZE: 
 The ulcer size of all 404 patients measured at the initial 
presentation showed a minimum size of 1 mm2 and maximum size of 64 
mm2 with a mean value of 10.91 mm2 ± 10.15 mm2 (1SD). 
 
TABLE NO: 10 
Parameter n Mean (SD) Min – Max 
Initial ulcer size 404 10.91 (10.15) 1 – 64 
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DEPTH OF THE ULCER: 
 Of the 404 patients, 312 (77.23%) patients had an ulcer depth of 
less than or equal to 33%. 87 (21.53%) patients had a much deeper ulcer 
measuring between 34 to 67%, whereas 5 (1.24%) patients had an ulcer 
depth measuring between 68 to 100%. 
 
TABLE NO: 11 
DEPTH OF 
INFILTRATE 
n (%) 
0 to 33 % 312 (77.23) 
34 to 67 % 87 (21.53) 
68 to 100 % 5 (1.24) 
Total 404 (100) 
 
GRAPH NO: 9 
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 The depth of the ulcer of 404 patients was compared with the 
causative micro-organism. Among the 87 eyes who presented with a 34 to 
67% of depth involvement, 49 (56.32%) were due to Aspergillus species. 
However, 4 (80%) out of 5 cases with 68 to 100% depth involvement 
were due to Fusarium species. The above results are statistically 
significant (p value <0.05). 
TABLE NO: 12 
Depth of 
Infiltrate 
Culture Organism P 
value f Fusarium n (%) 
Aspergillus 
n (%) 
Total 
n (%) 
0 to 33 % 192 (61.54) 120 (38.46) 312 (100) 
0.005 34 to 67 % 38 (43.68) 49 (56.32) 87 (100) 68 to 100 % 4 (80.00) 1 (20.00) 5 (100) 
Total 234 (57.92) 170 (42.08) 404 
F – Fisher’s exact test 
 
 The influence of recent topical medications over the depth of the 
ulcer was analysed. 
TABLE NO: 13 
Depth of 
infiltrate 
Recent topical medication 
P value f Yes 
n (%) 
No 
n (%) 
Total 
0 to 33 % 258 (82.69) 54 (17.31) 312 (100) 
0.357 34 to 67 % 77 (88.51) 10 (11.49) 87 (100) 68 to 100 % 5 (100) - 5 (100) 
Total 340 (84.16) 64 (15.84) 404 
F – Fisher’s exact test 
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PRESENCE OF HYPOPYON: 
 Hypopyon was noted in 53 (13.12%) eyes. 
 
GRAPH NO: 10 
 
 The presence or absence of hypopyon was analysed in relation to 
the causative micro-organism. Among the 53 eyes which presented with a 
hypopyon, 32 (60.38%) were due to Aspergillus species and 21 (39.62%) 
were due to Fusarium species. The results were statistically significant (p 
value <0.05). 
 
TABLE NO: 14 
Culture 
Hypopyon 
n(%) P valuec Yes No Total 
Fusarium 21 (8.97) 213 (91.03) 234 (100) 
0.004 Aspergillus 32 (18.82) 138 (81.18) 170 (100) 
Total 53 (13.12) 351 (86.88) 404 (100) 
C – Chi square test 
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TREATMENT ANALYSIS: 
All the 404 patients enrolled in the study were treated with topical 
antifungal medications and topical cycloplegics. The patients either 
received 5% natamycin as monotherapy or in combination with the above 
mentioned antifungal medications.  
Among the 404 patients, 154 (38.12%) patients were started on 5% 
Natamycin only, 180 (44.55%) patients received a combination of two 
drugs and 70 (17.33%) patients received more than two antifungal 
medications. 
GRAPH NO: 11 
 
One drug: 5% Natamycin 
Two drugs: 5% Natamycin + 1% Voriconazole or 5% Natamycin + 1% 
Itraconazole 
More than two drugs: Combination of above drugs  
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 Among the 312 ulcers with less than or equal to 33% depth 
involvement, 151 (48.40%) patients received only one drug (5% 
Natamycin), another 151 (48.40%) patients received two drugs. Among 
the 87 ulcers with 34 to 67% depth involvement, 28 (32.18%) patients 
received two drugs and 56 (64.37%) patients received more than two 
drugs. Of the 5 deep ulcers with 68 to 100% depth involvement, 4 (80%) 
patients received more than two drugs. The results were statistically 
significant (p value <0.05). 
TABLE NO: 15 
Depth of 
Infiltrate 
Drugs  
P 
valuef One drug n (%) 
Two 
drugs 
n (%) 
More than 
two drugs 
n (%) 
Total 
n (%) 
0 to 33 % 151 
(48.40) 
151 
(48.40) 
10  
(3.21) 
312 
(100) 
<0.001
34 to 67 % 3  
(3.45) 
28  
(32.18) 
56  
(64.37) 
87 
(100) 
68 to 100 % - 1  
(20.00) 
4  
(80.00) 
5  
(100) 
Total 154 
(38.12) 
180 
(44.55) 
70 
 (17.33) 
404 
F – Fisher’s exact test 
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VISUAL ACUITY: 
 The best corrected visual acuity (BCVA) at 3 months of all 404 
patients were analysed, the results are given below. The values ranged 
between 0 to 2.9 logMAR units, with an average of LogMAR 0.85 ± 0.80 
(1SD) units. 
 
TABLE NO: 16 
VISUAL 
ACUITY 
(LogMAR) 
n Mean (SD) Min – Max 
BCVA at 3 months 404 0.85 (0.80) 0 – 2.9 
 
 The initial visual acuity measured using Snellen’s chart at 6 meters 
were compared with the best corrected visual acuity at 3 months and the 
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details are given in the table below. The results were statistically 
significant (p value <0.05). 
TABLE NO: 17 
VISUAL 
ACUITY 
(logMAR) 
n Mean (SD) Min – Max P value* 
Initial VA 404 1.09 (0.67) 0.18 – 2.9 
< 0.01 BCVA at 3 
months 
404 0.85 (0.80) 0 – 2.9 
   *Wilcoxon sign rank test 
 
 The BCVA of patients at 3 months was compared between the 
Fusarium and the Aspergillus group. The final BCVA among the 
Fusarium group was better than the Aspergillus group, however there was 
no statistically significant difference between the groups. 
 
TABLE NO: 18 
CULTURE BCVA at 3 months n Mean (SD) Min – Max P value^ 
Fusarium 234 0.75 (0.68) 0 – 2.9 0.107 Aspergillus 170 0.98 (0.92) 0 – 2.9 
    ^Mann Whitney U test 
 
TIME TO RE- EPITHELIALIZATION: 
 Of the 404 patients, ulcers of 28 (6.93%) patients had healed at the 
end of 3 weeks. 
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TABLE NO: 19 
IMPRESSION AT 3 
WEEKS n (%) 
Healed 28 (6.93) 
Healing 295 (73.02) 
Remained same 45 (11.14) 
Worsened 36 (8.91) 
Total 404 
 
 Among the 28 patients, 15 (53.57%) ulcers were due to Fusarium 
species and 13 (46.43%) ulcers were due to Aspergillus species. 
 
TABLE NO: 20 
HEALED 
ULCERS 
n (%) CULTURE 
At 3 weeks 15 (53.57) Fusarium 13 (46.43) Aspergillus 
Total 28 (100)  
 
 At 3 months follow up the final end point was analysed. A total of 
354 (87.62%) ulcers had healed, 1 (0.25) ulcer remained same and 49 
(12.13%) ulcers had worsened. 
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TABLE NO: 21 
IMPRESSION AT 3 
MONTHS 
n (%) 
Healed 354 (87.62) 
Remained same 1 (0.25) 
Worsened 49 (12.13) 
Total 404 (100) 
 
GRAPH NO: 13 
 
  
The final end point of the 404 patients was compared with the 
depth of infiltrate at presentation. Among the 354 healed ulcers, 310 
(87.57%) patients had ulcers with less than or equal to 33% depth 
involvement. Among the 49 ulcers that had worsened, 42 (85.71%) ulcers 
had 34 to 67% depth involvement and 5 (10.20%) ulcers had 68 to100% 
depth involvement. The results were statistically significant (p value 
<0.05). 
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TABLE NO: 22 
END 
POINT 
DEPTH OF INFILTRATE 
P valuef 0 to 33 % 
n (%) 
34 to 67 
% 
n (%) 
68 to 100 
% 
n (%) 
Total 
Healed 310 
(87.57) 
44 
(12.43) 
- 354 (100) 
< 0.001 
Remained 
same 
- 1 (100) - 1 (100) 
Worsened 2 (4.08) 42 
(85.71) 
5 (10.20) 49 (100) 
Total 312 
(77.23) 
87 
(21.53) 
5 (1.24) 404 
F – Fisher’s exact test 
 
The final end point of the 404 patients was compared with the 
causative fungal micro-organism. Among the 354 healed ulcers, 218 
(61.58%) of them belonged to the Fusarium group and 136 (38.42%) 
belonged to the Aspergillus group. Among the 49 ulcers that worsened, 
16(32.65%) ulcers were due to Fusarium species and 33 (67.35%) ulcers 
were due to Aspergillus species. The results were statistically significant 
(p value <0.05). 
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TABLE NO: 23 
END POINT 
CULTURE 
P valuef Fusarium 
n (%) 
Aspergillus 
n (%) Total 
Healed 218 (61.58) 136 (38.42) 354 (100) 
0.009 
Remained 
same - 1 (100) 1 (100) 
Worsened 16 (32.65) 33 (67.35) 49 (100) 
Total 234 (57.92) 170 (42.08) 404 
F – Fisher’s exact test 
 
SCAR SIZE: 
The scar size of all 404 patients were measured at 3 months and it 
showed a minimum size of 1 mm2 and maximum size of 36 mm2 with a 
mean value of 4.46 mm2 ± 6.08 mm2 (1SD). 
 
TABLE NO: 24 
Parameter n Mean (SD) Min – Max 
Scar size at 3 
months 
404 4.46 (6.08) 1 – 36 
 
 The size of the ulcer at initial presentation was compared with the 
scar size at 3 months, the results were statistically significant (p value 
<0.05). 
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TABLE NO: 25 
Parameter n Mean (SD) Min – Max P value@
Initial ulcer 
size 
404 10.91 
(10.15) 
1 – 64 
< 0.01 
Final scar size 404 4.46 (6.08) 1 – 36 
@-Wilcoxon Sign rank test 
 
The results of the final scar size at 3 months were compared 
between the causative fungal micro-organism. The mean scar size among 
the Fusarium species was 4.34 mm2 ± 5.79 mm2 and those among the 
Aspergillus species was 4.56 mm2 ± 6.48 mm2. The results were 
statistically significant (p value <0.05). 
 
TABLE NO: 26 
CULTURE SCAR SIZE AT 3 MONTHS n Mean (SD) Min – Max P value^ 
Fusarium 234 4.34 (5.79) 0 – 36 0.039 Aspergillus 170 4.56 (6.48) 0 – 36 
 
 
ULCERS HEALED WITH MONOTHERAPY (NATAMYCIN): 
 Of the 404 patients, 154 (38.12%) of them healed with natamycin 
only, used as monotherapy. Among the 154 cases, 100 (64.94%) of them 
were due to Fusarium species, and 54 (35.06%) were due to Aspergillus 
species. 
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 Among the 180 patients who were started on two drugs at 
presentation, 175 (97.22%) patients healed and 5 (2.78%) patients did 
not. Among these 175 cases, 63 (36%) cases healed with a combination 
of natamycin and voriconazole, 112 (64%) cases healed with a 
combination of natamycin and itraconazole.  
 Among the 63 cases that healed with a combination of natamycin 
and voriconazole, 33 (52.38%) cases were due to Fusarium species and 
30 (47.62%) cases were due to Aspergillus species. 
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GRAPH NO: 15 
 
Among the 112 cases that healed with a combination of natamycin 
and itraconazole, 70 (62.50%) cases were due to Fusarium species and 42 
(37.50%) cases were due to Aspergillus species. 
 
GRAPH NO: 16 
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Among the 70 patients who were started on more than two drugs at 
presentation, 26 (37.14%) cases healed whereas 44 (62.86%) cases did 
not. 
Among the 26 cases that healed with more than two drugs, 15 
(57.69%) cases were due to Fusarium species and 11 (42.31%) cases 
were due to Aspergillus species. 
 
GRAPH NO: 17 
 
 
NON EFFECTIVE TREATMENT CAUSES: 
Perforation, impending perforation and worsening of ulcer were 
considered as causes of non effective treatment. They subsequently 
underwent therapeutic penetrating keratoplasty. 
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PERFORATION: 
 Among the 404 patients, 37 (9.16%) patients developed corneal 
perforation secondary to the fungal keratitis, among which 13 (35.14%) 
were due to Fusarium species and 24 (64.86%) were due to Aspergillus 
species. 
 
GRAPH NO: 18 
 
 
 Among the 37 cases which perforated, 28 (75.68%) of them 
happened at 3 weeks follow up and an additional 9 (24.32%) cases 
perforated at 1month follow up. 
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IMPENDING PERFORATION: 
 Among the 404 patients, 8 (1.98%) patients developed impending 
corneal perforation secondary to the fungal keratitis, among which 2 
(25%) were due to Fusarium species and 6 (75%) were due to Aspergillus 
species. 
 
GRAPH NO: 20 
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WORSENING OF ULCER: 
Among the 404 patients, 4 (0.99%) ulcers had worsened, among 
which 1 (25%) were due to Fusarium species and 3 (75%) were due to 
Aspergillus species. 
 
GRAPH NO: 21 
 
 
THERAPEUTIC PENETRATING KERATOPLASTY: 
Of the 404 patients, therapeutic penetrating keratoplasty was done 
in 49 (12.13%) patients.  
 
INDICATIONS: 
Among the 49 patients who underwent TPK, 37 (75.51%) of them 
was done due to perforation, 8 (16.33%) cases due to impending 
perforation and 4 (8.16%) cases due to worsening of the ulcer. 
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GRAPH NO: 22 
 
The distribution of causative fungal pathogen and need for 
therapeutic penetrating keratoplasty has been described in the table given 
below.  
 
GRAPH NO: 23 
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DISCUSSION: 
Mycotic keratitis remains a challenging and often elusive diagnosis 
in most geographic regions, especially endemic regions. Corneal 
infections due to fungi can be more virulent and damaging compared to 
that of bacteria. Corneal ulcers secondary to fungal infection are more 
likely to perforate the cornea than bacterial keratitis.  
Fusarium species and Aspergillus species are the most commonly 
reported fungal micro-organisms isolated from cases of fungal keratitis in 
the tropical countries. In both Ghana and south India the most commonly 
isolated fungal pathogens were Fusarium species. Fusarium species have 
also been found to be the principal fungal micro-organism in Florida, 
Paraguay, Nigeria, Tanzania, Hong Kong and Singapore. Aspergillus 
species predominate in northern India, Nepal, and Bangladesh. [3] 
Delays in diagnosis, sparse availability of antifungal medications 
and the hazardous sequelae of corneal fungal infections alter the course 
and outcome of the disease. Recent studies and advances in the specialty 
have broadened the approach and treatment of mycotic keratitis.  
Our study is designed to compare the treatment outcomes 
following Fusarium and Aspergillus keratitis in a tertiary eye care centre. 
A total of 404 patients were enrolled in the study, over a period of 
1 year. After careful clinical examination and appropriate microbiological 
diagnosis, patients were treated with antifungal medications. Among the 
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404 eyes, the mean age of patients was found to be 50.23 years in our 
study, (SD 9.95, range 20–70 years), with 43.56% of patients in the age 
group of 51 to 60 years. A study by Xie et al [7], showed almost one third 
of the patients (203) were in the age group of 41 to 50 years. A study by 
Chowdhary et al [10], showed the most commonly involved group to be 
between 31 to 40 years. 
In our study, 254 (62.87%) were males and 150 (37.13%) were 
females. A study by Xie et al [7], showed males (60.6%) were more likely 
to be affected by fungal keratitis than females (39.4%). A study by 
Chowdhary et al [10], showed 130 (68%) were males and 61 (32%) were 
females. Another study of 434 patients by Srinivasan et al [2], showed 266 
(61.3%) were males and 168 were females (38.7%). 
In our study, 264 (65.35%) patients were involved in agricultural 
work/ farming. A study by Srinivasan et al [2], showed that 245 (56.4%) 
patients were involved in agricultural work/ farming. 
Ocular trauma is a major predisposing factor for fungal keratitis 
and most cases are reported from developing countries such as India and 
Ghana. The percentage of corneal trauma has been reported to be as high 
as 66% by Srinivasan et al [2] and as low as 8% by Tanure et al [61]. In our 
study a history of antecedent trauma to the affected eye was present in 
178 eyes (44.06%). The most common agent causing trauma was found 
to be vegetative matter in 63 (35.39%) eyes. In a study by Chowdhary et 
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al [10], a history of prior injury to the cornea was noted in 63/150 cases 
(42%), with agricultural products in 33 (52.38%) eyes. In a study by Xie 
et al [7], corneal trauma was noted in 51.4% of patients, especially injury 
from plants (25.7%). In another study by Basak et al [17], a history of 
recent corneal injury was present in 994 (82.9%) patients, 715 (59.6%) 
patients had corneal injury with vegetative matter; mostly (526; 43.9%) 
paddy or paddy stalk. 
It is of interest that 42 (10.40%) of the total of 404 patients were 
recently exposed to some kind of native topical medication before initial 
presentation, mostly mother’s milk application in 18 (4.46%) eyes. In a 
study by Srinivasan et al [2], 162 patients had applied prior native topical 
medication, mostly mother’s milk being applied in 42 (25.93%) eyes. 
Preceding their initial visit to our hospital, 340 (84.16%) patients 
had applied topical medications in the form of antifungal, antibacterial 
and/or steroids, either alone or in combination. In a study by Srinivasan et 
al [2], 376 (86. 64%) patients had applied similar topical medications prior 
to presentation. 
In our study, 127 (31.44%) patients had an underlying systemic 
disease, amongst which 86 (67.72%) patients were diabetics. 
In our study, 53 (13.12%) eyes presented with a hypopyon, 32 
(60.38%) were due to Aspergillus species and 21 (39.62%) were due to 
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Fusarium species. In a study by Srinivasan et al [2], 232 patients (53.5%) 
had a hypopyon at presentation. 
Among the 404 patients in our study, 234 (57.92%) patients had 
positive culture for Fusasium species and 170 (42.08%) patients were 
found to be culture positive for Aspergillus species. In a study by 
Srinivasan et al [2], 73 (47.1%) patients were due to Fusarium species and 
25(16.1%) were due to Aspergillus species. In a study by Chowdhary et 
al [10], a diagnosis of mycotic keratitis was established in 191 (39%) cases 
out of the total study group of 485 cases. The spectrum of fungal isolates 
included were Aspergillus species in 78 (40.8%) cases followed by 
Curvularia species in 55 (28.6%) cases. In a study by Basak et al [17], 623 
fungal isolates were reported, 59.8% were Aspergillus species, 21.2% 
were Fusarium species, significantly reiterating the difference between 
northern and southern India. In a study by Xie et al [7], fungal isolates 
were of Fusarium species in 437 (73.3%) eyes and Aspergillus species in 
72 (12.1%) eyes. In the Mycotic Ulcer Treatment Trial by Prajna et al [4], 
the most common fungi isolated was Fusarium species in 128 patients 
(40%), followed by Aspergillus species in 54 patients (17%). 
In our study, there was a statistically significant improvement in 
the best corrected visual acuity at 3 months. 
In our study, 154 (38.12%) ulcers healed with natamycin only, 100 
(64.94%) of them were due to Fusarium species.  
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Among the 180 patients who were started on two drugs at 
presentation, 175 (97.22%) patients healed. Among these 175 cases, 63 
(36%) cases healed with a combination of natamycin and voriconazole, 
112 (64%) cases healed with a combination of natamycin and 
itraconazole.  
Among the 63 cases that healed with a combination of natamycin 
and voriconazole, 33 (52.38%) cases were due to Fusarium species and 
30 (47.62%) cases were due to Aspergillus species. Among the 112 cases 
that healed with a combination of natamycin and itraconazole, 70 
(62.50%) cases were due to Fusarium species and 42 (37.50%) cases 
were due to Aspergillus species. 
Among the 70 patients who were started on more than two drugs at 
presentation, 26 (37.14%) cases healed whereas 44 (62.86%) cases did 
not. Among the 26 cases that healed with more than two drugs, 15 
(57.69%) cases were due to Fusarium species and 11 (42.31%) cases 
were due to Aspergillus species. 
Among the 404 patients in our study, therapeutic penetrating 
keratoplasty was done in 49 (12.13%) patients. Indications were corneal 
perforation in 37 (75.51%) cases. In a study by chowdhary et al [10], 36 
patients (18.8%) required therapeutic penetrating keratoplasty. 
Indications for keratoplasty were corneal perforation in 26 eyes and 
worsening of the ulcer in 10 eyes. 
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CONCLUSION: 
Fusarium species remains to be the most commonly isolated fungal 
pathogen in southern India. However the incidence of Aspergillus species 
seems to be increasing. Fusarium species heals well with natamycin but 
Aspergillus species would fare better if voriconazole or itraconazole were 
used additionally. Aspergillus species are more virulent and have 
increased rates of corneal perforation. Standard therapy with polyenes 
still remains effective. Early diagnosis and effective treatment of fungal 
keratitis is the mainstay to prevent the visual threatening complications. 
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ABBREVIATIONS 
 
Logarithm of the minimum angle of resolution (logMAR) 
Best corrected visual acuity (BCVA) 
Standard deviation (SD) 
Potassium Hydroxide (KOH) 
Polymerase Chain Reaction (PCR) 
Therapeutic penetrating keratoplasty (TPK) 
  
 
EVALUATION FORM/ PROFORMA 
 
COMPARISON OF THE TREATMENT OUTCOMES FOLLOWING 
FUSARIUM AND ASPERGILLUS KERATITIS 
 
Study sample number:                                                      Date:  
Patient Details: 
1.  NAME  
2.  M. R. NUMBER  
3.  GENDER                      1. Male   2. Female 
4.  AGE  
5.  ADDRESS  
6.  CONTACT NUMBER  
 
Age: 
1. 20-30              2. 31-40            3. 41-50              4. 51-60             5. 61-70 
 
Occupation: 
1. Agricultural worker/farmer  
2. Labourer (heavy manual labour, lifting, loading) 
3. Tradesman/professional (mechanics, stone masons, electricians and 
welders. Also includes professions such as police, office workers, factory 
workers and drivers) 
4.  Unemployed 
5. Others: _________ 
OCULAR HISTORY: 
Affected eye:                       1. Right eye   2. Left eye     
Symptoms:         1. Yes     2. No   
Redness              Pain            Watering               Photophobia Blurring of vision                   
Others 
Recent trauma:                     1. Yes        2. No 
If yes,              
1. Vegetable matter      2. Thorn or tree branch      3. Animal matter (Cow’s tail, 
cow dung, insect)         4. Dust               5. Fingernail      6. Others: ________ 
Contact lens wear:              1. Yes         2. No 
 
SYSTEMIC HISTORY: 
1. Diabetes Mellitus        2. Hypertension         
3. Both DM and HTN    4. None 
Whether on treatment:              1. Yes        2. No 
Duration: _____ 
RECENT MEDICATIONS: 
Topical antifungals:       1. Yes        2. No 
YES/ 
NO 
NAME DOSAGE FREQUENCY DURATION 
 Natamycin    
 Voriconazole    
 Econazole    
 Amphotericin B    
 Fluconazole    
 Others    
 
Other topical medications:              1. Yes        2. No 
Name of the medication: ______________ 
Frequency: __________             Duration: ____________ 
Systemic antifungals:                       1. Yes        2. No 
Name of the medication: ________________ 
Frequency: _____________       Duration: ____________ 
Topical native medications:            1. Yes          2. No 
If yes,              
1. Mother’s milk    2. Oil     3. Chicken blood     4. Tongue            5. Nil 
H/o ocular surgery:                            1. Yes         2. No 
If yes, __________________ 
CLINICAL EXAMINATION: 
Date:  
TIME- POINT:                     
1. At enrollment        2. Every 3 days until re- epithelialization 
3. Every week till 3 weeks          4. At 1 month 
5. At 3 months                       6. Additional visits 
 
VISUAL ACUITY: 
 
 At presentation At 3 weeks At 3 months 
Uncorrected visual acuity 
(UCVA) 
   
Best corrected visual acuity 
(BCVA) 
   
OCULAR EXAMINATION: 
I. Eyebrows/ lids/ adnexa:        1. Yes    2. No 
Madarosis                               Blepharitis 
Trichiasis                                Meibomitis 
Ectropion                                Entropion 
Lagophthalmos                       Dacryocystitis 
Others:   _________ 
 
II. Conjunctiva:                      1. Yes    2. No 
Circum corneal congestion 
Chemosis 
Others:  ________ 
 
III. Anterior chamber:            1. Yes    2. No 
Cells            If yes,          
a. 0     b. 0.5+     c. 1+     d. 2+     e. 3+     f. 4+ 
Flare            If yes,  
a. 0     b. 1+     c. 2+     d. 3+     e. 4+ 
Others:   _______ 
 
IV. Iris:                                  
1. Normal    2. Abnormal 
 
V. Pupil:                                1. Yes    2. No  
Reaction to light 
 
VI. Lens:                               1. Yes    2. No 
Visualised 
If yes,            1. Cataract present         2. Cataract absent 
 
Posterior segment evaluation:  
1. Normal       2. Abnormal       3. Not examined 
 
IOP ( Digital Tonometry) :     
1. Normal       2. Increased        3. Decreased 
Duct of the affected eye:  
1. Free      2. Not free with clear fluid 
3. Not free with pus        4. None 
 
RBS: ________ mg% 
 
 
 
 
 
 
 
 
EXAMINATION OF CORNEA: 
DRAWING: 
 
 
 
 
 
 
 
 
 
Site of the ulcer: 
1. Entirely in the periphery 
2. Overlapping the central 4-mm circle and periphery without filling the 
centre 
3. Entirely in the central 4-mm circle 
4. Completely filling the 4-mm circle and extending to the periphery. 
 
 
Longest 
diameter in 
mm 
Longest perpendicular 
width in mm 
Size of epithelial defect   
Size of stromal 
infiltrate/ scar 
  
 
Time to re- epithelialization: (To be filled in during follow- up visits only) 
________ 
Infiltrate/ scar depth: 
1. No infiltrate/ scar                  2. 0-33% depth 
3. >33-67% depth                     4. >67-100% depth 
 
Hypopyon:               1.Yes       2. No    
If yes, height: _____ mm 
 
Other clinical findings:      1. Yes    2. No 
Raised lesion            Satellite lesions          Feathery margins 
Endothelial plaque          Immune ring 
Absence of corneal sensation           
 
Clinical impression: 
1. Healed     2. Healing     3. Remained same     4. Worsened 
 
 
 
 
 
 
 
 
 
MICROBIOLOGICAL REPORT: 
Date:  
 
TIME- POINT:            1. At enrollment         2. Repeat culture 
 
CORNEAL SMEAR: 
10% KOH:           1. Fungus present         2. Fungus absent 
GRAM’S:             1. Bacteria present       2. Bacteria absent 
                              3. Fungus present        4. Fungus absent 
 
CULTURE: 
MEDIA RESULT 
Sheep’s blood agar  
Potato dextrose agar  
 
Lactophenol cotton blue staining report: 
 
 
 
DIAGNOSIS:               1. Fusarium        2. Aspergillus 
 
 
 
 
TREATMENT GIVEN: 
1. Topical 5% Natamycin 
2. Topical 1% Voriconazole 
3. Topical 2% Econazole 
4. Topical 0.15% Amphotericin B 
5. Topical 1 % Itraconazole 
6. Systemic antifungals 
7. Intrastromal antifungal injection 
DRUG DATE 
STARTED
DOSAGE FREQUENCY DURATION
Topical 5% 
Natamycin 
    
Topical 1% 
Voriconazole 
    
Topical 2% 
Econazole 
    
Topical 0.15% 
Amphotericin B  
    
Topical 1 % 
Itraconazole 
    
Systemic 
antifungals 
    
Intrastromal 
antifungal injection 
    
 
 
 
PERFORATION:         
1. Yes            2. No                  Date:  
 
Duration between presentation to the hospital and date of perforation:                              
 
 
THERAPEUTIC PENETRATING KERATOPLASTY: 
1. Yes            2. No  
Operated on:   
 
Indication:  
1. Perforation         2. Impending perforation 
3. Worsening of ulcer 
 
Outcome:               
1. Clear graft       2. Failed graft         3. Graft infiltrate 
 
 
 
CONSENT FORM 
 
Informed Consent form to participate in a clinical study. 
Study Title: COMPARISON OF THE TREATMENT OUTCOMES 
FOLLOWING FUSARIUM AND ASPERGILLUS KERATITIS.  
Protocol Number: 
 Subject’s Name: ________________ 
Subject’s Initials: _______________  
Subject ID No: _________________  
 
  Please put initial in the 
box (Subject) 
 
(i) I confirm that I have understood the 
information about the study, 
procedures and treatments for the 
above study and have had the 
opportunity to ask questions and I 
received satisfactory answers to all of 
my questions.  I have been given a 
copy of the informed consent form to 
take home  
   
[         ] 
 
(ii) I understand that my participation in 
the study is voluntary and that I am 
free to withdraw at any time, without 
giving any reason, without my medical 
care or legal rights being affected. 
However, this is may  not be possible 
for certain surgical procedures   
 
[         ] 
 
(iii) I understand that the Investigator of 
the study to access my health records 
for the research purpose. However, I 
understand that my identity will not be 
revealed in any information released to 
third parties or published.  
 
[         ] 
 
(iv) I agree not to restrict the use of any 
data or results that arise from this 
study provided such a use is only for 
scientific purpose(s)  
 
[         ] 
 
(v) I agree to take part in the above study.  
   
[         ] 
 
 
 
Signature (or Thumb impression) of the Subject:  
Subject’s Name: 
Date:  
 
Signature (or Thumb impression) of 
Legally Acceptable Representative (LAR): 
Date:  
 
Signature of the Investigator:  
Investigator’s Name: 
Date:  
 
Signature of the Witness: 
Name of the Witness: 
Date: 
 
 
 
 
 
         
 
 
Urkund Analysis Result 
Analysed Document: THESIS COMPLETED FINAL DOC 2017.doc (D31002227)
Submitted: 10/4/2017 11:59:00 AM 
Submitted By: siva7darshan@gmail.com 
Significance: 1 % 
Sources included in the report: 
pli.docx (D30910374) 
https://en.wikipedia.org/wiki/Echinocandin 
Instances where selected sources appear: 
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1 CHANDRA DEVI 2 55 4 1 2 1 1 2 1 1 5 2 4 60 1 82 4 6*3 3 2 1 1 1,2
2 PIDARI 2 45 3 1 2 2 2 4 2 5 2 6 60 1 117 2 3*3 2 2 1 2 1
3 PANJAVARNAM 2 54 4 1 1 1 2 2 1 1 1 2 HM 1 97 4 7*7 3 1 1 1 1,2,5
4 CHANDRAN A 1 45 3 1 1 1 1 2 4 1 5 2 6 36 1 84 2 2*2 2 2 1 1 1
5 CHINNA 1 48 3 1 1 2 2 1 1 5 2 5 60 1 90 3 4*4 2 2 1 2 1,5
6 BALASUBRAMANI S 1 44 3 2 2 1 2 2 2 1 5 2 1/2 60 1 151 4 6*7 3 1 1 2 1,2,5
7 NAGAMMA 2 52 4 1 1 1 1 2 4 1 5 1 5 60 1 86 3 4*4 2 2 1 1 1,5
8 ANWAR BATCHA 1 56 4 3 1 1 1 2 1 1 5 2 6 24 1 106 2 2*2 2 2 1 1 1
9 VALLIAMMAI G 2 20 1 1 1 2 2 4 1 5 2 6 18 1 97 1 1*2 2 2 1 1 1
10 KALIAMMAL S 2 48 3 1 1 2 2 2 2 5 1 4 60 1 81 4 5*3 3 1 1 1 1,5
11 PRITHVIRAJ C 1 22 1 4 2 1 1 2 4 1 5 2 5 60 1 80 3 3*3 2 2 1 1 1
12 MUNIYASAMY 1 65 5 1 1 1 3 2 1 1 4 2 1 60 1 85 4 7*7 3 1 1 2 1,2
13 VEERANAN A 1 50 3 2 1 1 2 2 4 2 5 2 4 60 1 140 4 3*3.5 2 2 1 1 1,5
14 SUBBAIAH P 1 56 4 2 2 1 1 2 2 2 5 2 5 60 1 110 3 2*2 3 2 2 2 1
15 SEENI S 1 25 1 4 1 2 2 4 1 5 2 6 24 1 120 2 2*3 2 2 1 2 1,5
16 MURUGAN M 1 43 3 1 2 1 1 2 3 2 5 2 6 60 1 140 2 3*2 2 2 1 1 1,5
17 RACKKI A 2 47 3 2 2 1 2 2 2 1 5 1 FCF 1 110 4 5*7 3 1 1 2 1,5
18 JILANI 2 55 4 1 1 1 1 2 4 1 5 2 PL PR 1 139 4 6*6 3 1 1 2 1,2
19 RAJU S 1 52 4 3 1 1 2 2 3 1 5 2 1 60 1 294 4 5*6 3 1 1 2 1,2
20 CHINNAIAH D 1 49 3 3 1 1 1 2 1 1 5 2 6 60 1 137 3 3*3 2 2 2 1 1,5
21 ALAGARSAMY 1 52 4 2 1 2 2 4 1 5 2 5 60 1 145 4 5*3 3 2 1 1 1,2,5
22 MALLIKA C 2 45 3 1 1 1 2 2 4 1 1 2 5 60 1 172 3 2*2 2 2 1 2 1
23 UMADEVI 2 45 3 1 2 2 2 4 1 5 2 6 12 1 126 1 2*1 2 2 1 1 1
24 POOPANDI 1 58 4 1 2 2 2 4 1 5 2 6 36 1 134 2 2*2 2 2 1 1 1
25 SUKHIBAI 2 45 3 1 1 1 5 2 2 1 5 2 6 60 1 142 3 3*4 3 2 1 2 1,5
26 CHINNAPONNU 2 49 3 1 2 1 1 2 4 1 5 1 3 60 1 102 4 3*6 2 2 1 2 1,5
27 CHINNAKARUPPAN 1 27 1 1 1 2 2 3 1 5 2 6 24 1 140 2 2*2 2 2 1 1 1
28 SAIKUMAR K 1 55 4 2 2 2 2 4 1 5 2 2 60 1 127 4 5*7 3 1 1 2 1,5
29 MUTHUSAMY P 1 50 3 2 1 1 2 2 1 1 5 1 HM 1 110 4 7*6 4 1 1 1 1,2,5
30 HARINATH M 1 62 5 1 2 2 2 4 1 5 2 3 60 1 113 4 5*6 2 2 1 1 1,5
31 VIGNESH M 1 30 1 3 2 1 5 2 4 1 5 2 6 60 1 140 3 4*4 2 2 1 1 1
32 KARUPPATHAL N 2 42 3 1 2 1 1 2 1 1 5 2 PL 1 150 4 6*6 3 1 1 1 1,5
33 MUNIYAPPAN R 1 55 4 2 2 1 3 2 4 1 5 2 6 18 1 130 2 3*2 2 2 1 1 1
34 MADASAMY M 1 47 3 2 1 1 1 2 3 1 5 2 FCF 1 102 4 5*7 2 1 2 2 1,2
35 CHINNAIAH P L 1 65 5 1 1 2 2 4 1 5 2 5 60 1 110 3 2*2 2 2 1 1 1
36 RAJIYA BEGUM A 2 55 4 1 1 2 2 1 1 5 2 6 18 1 119 2 2*1 2 2 1 2 1
37 THIRUMALAI V 1 47 3 1 1 2 2 1 1 5 2 6 60 1 83 3 3*2 2 2 1 1 1,5
38 MUTHURAJ A 1 60 4 1 1 1 2 2 1 1 5 2 PL 1 100 4 6*8 4 2 1 2 1,2,5
39 RUCKMANI P 2 45 3 1 2 1 1 2 3 1 5 2 5 60 1 82 2 3*3.5 2 2 1 2 1
40 KANNAN A 1 60 4 4 2 2 2 4 1 5 1 6 24 1 117 2 2*2 2 2 1 1 1
41 MANI M 1 65 5 2 2 1 3 2 1 1 1 2 6 18 1 145 1 2*2 2 2 1 1 1
42
VENKATA 
SUBBAREDDY 1 62 5 1 2 1 1 2 4 1 5 2 5 60 1 137 2 3*2 2 2 1 2 1
43 PONNAN T 1 55 4 1 1 2 2 2 1 5 1 6 36 1 112 2 4*4 2 2 1 1 1,5
44 SHANTHI S 2 45 3 1 1 2 2 3 1 5 2 5 60 1 95 2 3*3.5 2 2 1 1 1,5
45 SHANTHI S 2 58 4 1 2 1 2 2 1 1 5 2 6 60 1 140 2 3*3 2 2 1 2 1
46 MAYILATHAL 2 65 5 1 1 2 2 4 1 5 2 4 60 1 107 4 4*5 2 2 1 2 1,5
47 NAGARAJU 1 55 4 1 2 1 5 2 4 1 5 2 6 36 1 145 2 4*4 2 2 1 1 1
48 MARIAMMAL K 2 53 4 1 2 1 1 2 4 1 5 2 6 36 1 102 2 2*2 2 2 2 2 1
49 ESWARAIAH N 1 54 4 4 2 1 1 2 4 1 5 2 5 60 1 100 3 3*3 2 2 1 1 1
50 RAMANA G 1 55 4 1 1 2 2 4 1 5 2 6 36 1 117 3 3*3 3 2 1 2 1
51 MARIAMMAL R 2 46 3 1 1 1 3 2 1 1 5 2 6 60 1 89 2 2*2 2 2 1 2 1,5
52 MUTHU K 1 50 3 2 1 1 3 2 4 1 5 2 5 60 1 124 3 4*4 2 2 1 1 1,5
53 SUBRAMANIAN S 1 35 2 1 1 1 1 2 4 1 5 2 5 60 1 241 2 4*3 2 2 1 1 1,5
54 SUBRAMANI V 1 58 4 1 2 2 2 4 1 5 1 6 24 1 104 2 4*4 2 2 1 2 1,5
55 SURESH KUMAR M 1 45 3 2 2 1 2 2 4 1 5 2 6 36 1 78 2 3*3 2 2 1 1 1
56 RAMU U 1 41 3 2 2 2 2 4 2 5 2 6 18 1 72 2 1.5*1.5 2 2 1 1 1
57 SINGARAVEL P 1 56 4 1 1 1 5 2 1 1 5 1 6 60 1 88 3 5*3 3 2 1 1 1,5
58 SIVAPPURAJA T 1 42 3 1 2 2 2 4 1 5 2 6 18 1 83 1 3*3 2 2 1 2 1,2
59 CHINNAMMAL E 2 65 5 1 2 1 3 2 4 1 1 2 FCF 1 100 4 5*6 3 1 1 2 1,2,5
60 VENKATALAKSHMI 2 53 4 1 1 2 2 4 1 5 2 6 60 1 82 2 3*3.5 2 2 1 1 1
61 PENCHALAIAH 1 55 4 2 1 1 3 2 4 1 5 2 1/2 60 1 117 4 7*5 3 1 1 1 1,2,5
62 AMARAVATHI K 2 50 3 2 1 2 2 4 2 5 2 6 60 1 97 5 4*4 2 2 2 2 1,2
63 JEYANTHI P 2 68 5 2 1 2 2 4 1 5 2 3 60 1 84 4 5*5 2 2 2 1 1,5
64 SANKAR V 1 60 4 1 2 2 2 3 2 5 2 6 18 1 90 2 4*4 2 2 1 1 1,5
65 MOHAN V 1 25 1 4 1 1 1 2 4 1 5 2 6 60 1 151 3 3*3.5 2 2 1 2 1,5
66 MURUGAN K 1 60 4 1 2 2 2 1 1 5 2 5 60 1 86 3 5*3 3 2 1 2 1,2,5
67 MONICKA 2 28 1 3 2 2 2 4 2 5 2 6 18 1 106 1 2*1 2 2 1 1 1
68 MUTHULAKSHMI S 2 63 5 1 1 1 4 2 4 1 5 1 6 60 1 97 2 2*2 2 2 1 1 1,2
69 GANESAN N 1 56 4 1 1 2 2 4 1 5 2 6 12 1 81 1 2*2 3 2 1 2 1,5
70 PAPPATHI A 2 45 3 1 2 1 2 2 4 1 5 2 5 60 1 80 3 3*3 3 2 1 1 1,5
71 UNNAMALAI 1 55 4 1 1 1 3 2 4 1 2 1 6 24 1 100 2 3*3 2 2 1 2 1,5
72 MUNIYAMMAL M 2 42 3 1 2 1 1 2 1 1 5 2 5 60 1 117 3 2*4 2 2 1 1 1,2,5
73 TAMILSELVI U 2 60 4 1 1 2 2 2 1 5 2 6 12 1 89 2 2*2 2 2 1 1 1
74 ARUNA M 2 65 5 1 2 2 2 4 1 5 2 6 24 1 124 1 2*2 2 2 1 2 1,5
75 VADIVEL K 1 65 5 1 1 2 2 4 1 5 2 5 60 1 249 3 4*3 2 2 1 1 1,5
76 PANDIYAN M 1 58 4 1 1 1 3 2 4 1 2 2 6 60 1 150 3 4*4 3 2 2 1 1,5
77 NATCHAMMAI C 2 49 3 1 1 1 4 2 4 1 5 2 6 24 1 102 3 3*3 2 2 1 1 1
78 IYAPPAN S 1 52 4 3 2 2 2 4 1 5 2 6 24 1 100 2 1.5*1.5 2 2 1 2 1
79 ANTHONI SAMY Y 1 70 5 1 1 1 1 2 4 2 5 2 4 60 1 117 4 5*3 3 2 1 2 1,5
80 SAHAYA RAJ L 1 54 4 2 2 2 2 2 1 5 2 6 60 1 89 2 3*3 2 2 1 1 1,5
81 MUKILA M 2 55 4 2 2 1 2 2 4 1 5 2 5 60 1 124 2 2*2 2 2 1 1 1
82 CHELLADURAI M 1 60 4 2 2 2 2 4 1 5 1 6 18 1 96 2 3*3.5 2 2 1 2 1,2
83 CHANDRA SEKHAR G 1 58 4 1 1 1 3 2 2 1 5 2 6 9 1 126 1 2*2 2 2 1 1 1
84 RUCKMANI P 2 45 3 1 1 2 2 4 1 5 2 6 36 1 217 2 2*3 2 2 1 1 1,2,5
85 PALANIVEL K 1 50 3 1 1 1 3 2 4 1 3 1 5 60 1 267 2 3*3 2 2 1 2 1,5
86 MUNEESWARAN N 1 60 4 1 2 2 2 4 1 5 2 6 18 1 200 2 2*2 2 2 1 2 1,2,5
87 SEETHALAKSHMI M 2 42 3 1 1 2 2 3 1 5 2 6 60 1 147 3 2*2 2 2 1 1 1
88 GOVINDAN V 1 45 3 1 2 2 2 1 1 5 2 5 60 1 120 3 4*4 2 2 1 1 1,5
89 BOOMI V 1 55 4 1 2 1 3 2 4 1 5 2 2 60 1 110 4 4*5 3 2 1 2 1,2,5
90 GOMATHY C 2 32 5 1 1 1 3 2 4 1 5 2 1/2 60 1 108 4 4*4 3 1 2 2 1,2,5
91 KARUPPAYEE N 2 50 3 1 2 1 2 2 2 1 5 2 6 60 1 98 4 3*3 2 2 1 1 1,5
92 AMMALU 2 64 5 2 1 2 2 4 1 5 2 6 60 1 102 2 1.5*1.5 2 2 2 2 1
93 ARUL PRAKASH S 1 51 4 2 2 2 2 4 2 5 2 6 18 1 100 1 2*2 2 2 1 1 1,5
94 MANI A 1 41 3 2 2 1 5 2 4 1 5 2 6 24 1 117 2 2*1 2 2 1 2 1
95 VENKATESH V 1 55 4 1 1 2 2 2 1 5 2 5 60 1 89 3 2*2 2 2 1 1 1
96 KALIDASS M 1 43 3 1 1 1 1 2 4 1 4 1 5 60 1 124 2 3*3.5 3 2 1 1 1,5
97 ARUMUGAM P 1 67 5 4 1 1 3 2 4 1 5 2 6 60 1 249 2 2*2 2 2 1 1 1,5
98 KRISHNAN 1 24 1 3 1 2 2 1 2 5 2 6 36 1 100 2 2*4 2 2 1 2 1,2
99 PITCHAI DEVAR 1 48 3 1 1 1 4 2 1 1 5 1 5 60 1 83 3 3*2 2 2 1 2 1
100 KUMAR S 1 28 1 3 2 1 1 2 4 1 5 2 6 24 1 116 2 2*3 2 2 1 2 1,5
101 ARUL DASS D 1 46 3 1 2 1 2 4 2 5 2 6 18 1 128 2 2*1 2 2 1 1 1
102 PANDI P 1 53 4 1 1 2 2 4 1 5 2 5 60 1 110 2 3*3 2 2 1 2 1,2
103 MURUGESAN K 1 30 1 3 2 1 3 2 4 1 5 2 6 24 1 79 2 2*2.5 2 2 1 1 1
104 MOHAMMED ASMI S 1 35 2 2 1 2 2 4 2 5 2 6 24 1 80 1 1.5*1 2 2 2 1 1
105 SEKAR M 1 55 4 2 1 2 2 4 2 5 2 6 60 1 80 3 3*3 2 2 2 1 1,5
106 KASIM G 1 48 3 1 1 2 2 4 1 5 2 6 36 1 79 3 2*2 2 2 1 2 1
107 ANNAKILI V 2 57 4 1 2 1 2 2 4 1 1 2 5 60 1 98 3 3*3.5 2 2 1 2 1
108 SANKARAN V 1 36 2 2 1 2 2 1 1 5 2 6 36 1 112 1 2*2 2 2 1 1 1
109 RUTHIRA MOORTHY S 1 57 4 1 2 2 2 4 2 5 2 5 60 1 89 3 4*4 3 2 1 1 1,5
110 KARUKKAVEL I 1 55 4 1 1 1 4 2 1 1 5 1 6 60 1 110 3 2*2 2 2 1 1 1
111 MANIKANDAN K 1 35 2 3 1 2 2 4 1 5 2 6 60 1 78 3 1.5*1.5 2 2 1 1 1
112 GOVINDAMMAL K 2 60 4 1 2 1 1 2 4 1 2 2 6 60 1 150 2 5*3 2 2 1 2 1,5
113 PALANISAMY 1 50 3 1 2 1 3 2 3 1 2 1 PL 1 93 4 6*7 3 1 1 1 1,2,5
114 NAGARAJAN R 1 45 3 3 1 2 2 1 1 5 2 6 18 1 120 2 2*2 2 2 1 1 1,5
115 SEENAIAH V 1 58 4 1 1 2 2 1 1 5 2 6 18 1 142 2 2*2 2 2 1 1 1
116 DEVDASS S 1 43 3 1 2 1 3 2 4 2 5 2 5 60 1 99 3 1.5*1.5 2 2 1 2 1
117 MARY LAISHA 2 47 3 1 2 1 4 2 4 1 5 2 6 18 1 108 2 5*3 3 2 2 1 1,5
118 CHITRA N 2 55 4 1 2 2 2 4 1 5 2 6 60 1 200 4 3*3 2 2 2 1 1,2
119 PITCHAI KALAI P 1 60 4 2 1 2 2 4 1 5 2 6 24 1 135 2 4*4 2 2 1 2 1,5
120 RAJANGAM 1 57 4 1 2 1 1 2 4 1 5 2 HM 1 153 4 5*5 3 1 1 2 1,2
121 ANUSIYA DEVI M 2 40 2 1 1 2 2 2 1 5 2 6 24 1 79 2 2*2 2 2 1 2 1
122 RAVICHANDRAN P 1 55 4 2 1 1 3 2 4 2 5 2 6 24 1 156 1 1.5*1.5 2 2 1 1 1
123 MUTHUKUMAR R 1 50 3 3 2 1 3 2 1 1 5 2 5 60 1 245 4 5*3 2 1 1 2 1,5
124 ARRANGANATHAN R 1 52 4 2 1 2 2 4 1 5 1 6 60 1 157 4 2*2 2 2 1 1 1
125 SIVAIAH T 1 50 3 1 2 1 2 2 3 1 5 2 5 60 1 246 2 3.5*3.5 2 2 1 2 1,5
126 CHINNA DURAI S 1 40 2 3 1 2 2 4 2 5 2 6 60 1 142 3 4*2 2 2 2 1 1,2
127 SAKILA DEVI A 2 35 2 2 1 1 5 2 4 2 5 1 6 60 1 154 3 4*2 2 2 1 1 1,2
128 PONNAMMAL K 2 45 3 1 1 2 2 4 1 5 2 6 36 1 106 4 2*3 2 2 1 2 1,2
129 ALAGARSAMY S 1 52 4 3 2 1 1 2 4 1 3 2 HM 1 100 4 6*3 3 1 1 2 1,2,5
130 PONNANDI V 1 48 3 1 1 1 3 2 3 1 2 2 4 60 1 162 3 5*5 3 1 1 1 1,2,5
131 VINOTH KUMAR I 1 55 4 2 1 1 3 2 4 1 5 2 6 60 1 124 3 2*2 2 2 1 1 1
132 JEYA MANI P 2 40 2 1 1 2 2 4 1 5 2 6 60 1 420 2 3*3 2 2 2 2 1,2,5
133 MARIAMMAL P 2 37 2 1 2 1 1 2 4 2 5 2 5 60 1 17 3 3*3 2 2 1 1 1
134 VIVEKANANTHA S 1 60 4 2 2 2 2 3 1 5 2 5 60 1 145 2 3*2 3 2 1 1 1
135 GUNASEELAN M 1 50 3 2 1 2 2 4 1 5 2 6 60 1 137 3 4*4 2 2 1 2 1,2
136 RAMANAMMA C 2 60 4 1 2 1 2 2 1 1 5 2 6 18 1 112 2 2*2 2 2 1 1 1,2
137 PANDIAMMAL K 2 65 5 1 1 1 1 2 4 1 5 2 PL 1 113 4 6*6 3 2 2 1 1,2,5
138 BALAMANI M 2 58 4 1 2 1 3 2 4 1 5 1 PL 1 140 4 6*7 3 1 1 1 1,2,5
139 HAJEE AKBAR M 1 38 2 2 2 1 4 2 4 1 5 2 6 24 1 107 2 2*2 2 2 1 1 1,2
140 PALANISAMY C 1 60 4 4 1 2 2 4 2 5 2 5 60 1 145 2 2*4 2 2 1 2 1,5
141 RAJENDRAN M S 1 55 4 3 1 2 2 4 1 5 1 3 60 1 102 4 3*3 2 1 1 2 1,5
142 BALAMURUGAN S 1 45 3 1 2 1 1 2 4 1 4 2 6 60 1 100 2 3*2 2 2 1 1 1
143 SEVAGAN A 1 42 3 1 1 2 2 3 1 5 2 6 24 1 117 2 3*3 2 2 1 1 1
144 VELAISAMY L 1 55 4 1 1 2 2 1 1 5 2 6 36 1 89 2 3*2 2 2 1 1 1,5
145 PANCHABATLA VENU 1 45 3 2 2 1 3 2 4 1 5 2 6 9 1 124 1 1*2 2 2 1 2 1,2
146
KALYANA SUNDARAM 
S 1 42 3 3 2 1 2 2 4 1 5 2 6 60 1 241 3 2*3 2 2 2 1 1,5
147 NITHIKUMAR M 1 52 4 2 2 1 4 2 4 1 5 2 6 36 1 104 2 2*2 2 2 2 2 1,5
148 MURUGAN P 1 55 4 3 2 1 2 2 4 1 5 2 5 60 1 120 2 3*3 2 2 1 2 1
149 MUNIYANDI K 1 43 3 1 2 2 2 3 1 5 2 6 12 1 102 2 1*1 2 2 1 1 1
150 CHELLATHAI 2 67 5 1 1 1 5 2 4 2 5 2 HM 1 100 3 6*5 3 2 2 1 1,2,5
151 ALPHONSE MARY S 2 55 4 1 1 1 2 2 2 1 5 2 1 60 1 117 4 6*6 3 1 1 2 1,2,5
152 PALRAJ K 1 37 2 1 2 2 2 4 1 5 1 6 18 1 89 2 2*2 2 2 1 2 1
153 KATHIRI VEL G 1 54 4 1 2 2 2 4 1 5 2 6 24 1 124 2 2*3 2 2 1 1 1
154 CHELLATHAI 2 44 3 1 1 1 4 2 4 1 5 2 6 18 1 249 1 1*2 2 2 1 2 1
155 VALARMATHI R 2 50 3 1 2 1 4 2 1 1 1 1 PL 1 100 4 6*5 3 1 2 2 1,2,5
156 VELAYEE K 2 60 4 4 2 2 2 4 2 5 2 6 18 1 83 2 2*1 2 2 1 2 1,2,5
157 VARADHARAJAN K 1 45 3 2 2 1 3 2 4 1 5 2 6 60 1 116 4 3*3 2 2 2 2 1,2
158 MOHAMED AFRIDI K 1 54 4 3 1 2 2 4 1 5 2 6 24 1 110 1 3*3 2 2 1 2 1
159 ADHI NARAYANAN CH 1 44 3 3 2 1 1 2 3 1 5 2 HM 1 112 4 5*5 3 1 1 2 1,2,5
160 LAKSHMI A 2 55 4 4 2 2 2 4 1 5 2 6 60 1 85 3 4*2 2 2 2 1 1,2
161 VENKATA RAO Y 1 35 2 1 2 1 1 2 4 1 5 2 PL 1 220 4 4*5 4 1 1 1 1,2,5
162 PENCHALAIAH N 1 65 5 1 1 2 2 4 1 5 2 6 18 1 240 2 2*2 2 2 1 2 1,2
163 AJITH M 1 25 1 4 1 1 5 2 2 1 5 2 6 24 1 200 2 2*2 2 2 1 1 1
164 INDIRAN C 1 44 3 1 2 2 2 4 1 5 2 HM 1 356 4 6*5 3 2 1 2 1,2,5
165 NAZEER HUSSAIN S 1 37 2 3 2 1 2 2 4 1 5 2 6 24 1 118 2 2*2 2 2 1 1 1
166 CHINNATHAMBI 1 65 5 4 2 1 3 2 4 1 5 1 6 60 1 99 2 3*3 2 2 1 2 1
167 SAHAYAMARY A 2 57 4 1 1 2 2 1 1 5 2 FCF 1 120 4 6*4 3 2 1 2 1,2,5
168 JOHN S 1 55 4 3 1 2 2 4 1 5 2 6 18 1 118 1 2*1 2 2 2 1 1
169 KARUPPAIAH A 1 54 4 1 1 2 2 4 1 5 1 6 36 1 100 2 2*2 2 2 1 2 1,5
170 SWAMINATHAN 1 60 4 1 1 1 1 2 4 1 5 2 HM 1 99 3 6*5 3 1 1 1 1,2,5
171 AYYANAR K 1 45 3 1 2 2 2 2 1 5 2 6 24 1 90 3 2*2 2 2 1 2 1
172 ARUNACHALA THAI 2 50 3 1 2 2 2 4 1 5 2 6 60 1 92 2 3*3 2 2 1 1 1
173 GANESAN V 1 60 4 1 2 1 4 2 1 2 5 2 6 60 1 90 2 3*3 2 2 1 2 1
174 MUTHUPANDI A 1 48 3 1 2 1 1 2 2 1 4 2 HM 1 97 4 5*6 3 1 2 1 1,2,5
175 PERIYASAMY 1 47 3 1 2 1 5 2 4 1 5 2 6 18 1 124 2 2*1 2 2 1 2 1
176 MUTHURAMAN K 1 55 4 1 2 2 2 4 1 5 2 6 36 1 329 2 2*1 2 2 1 2 1
177 MARKKANDAN O 1 60 4 2 2 2 2 4 1 5 2 6 24 1 102 2 2*2 2 2 1 1 1
178 RAMANA REDDY 1 50 3 2 1 2 2 4 1 5 2 6 60 1 100 3 3*2 2 2 1 2 1,2
179 LALITHA 2 38 2 2 2 1 3 2 4 1 5 2 HM 1 117 4 4*4 2 1 1 1 1,2,5
180 KRISHNAMMAL A 2 51 4 1 2 1 2 2 4 2 5 2 6 60 1 89 2 2*3 2 2 2 2 1,2
181 CHINNAMMAL R 2 45 3 1 1 2 2 2 1 5 1 6 18 1 124 2 1*2 2 2 1 2 1
182 NAGAMMAL V 2 55 4 1 2 2 2 4 1 5 2 6 36 1 249 2 2*3 2 2 1 1 1,2
183 VELLAIAMMAL V 2 45 3 1 1 2 2 4 1 5 2 5 60 1 150 3 3*3 3 2 1 1 1,5
184 AKKINI S. 1 65 5 4 2 1 1 2 3 1 5 1 6 36 1 102 2 2*2 2 2 1 1 1
185 BOOMINATHAN M. 1 60 4 1 2 2 2 4 1 5 2 6 9 1 100 1 1*1 2 2 1 2 1
186 CHELLAMMAL P. 2 46 3 1 1 2 2 2 1 5 2 HM 1 117 4 5*6 3 1 1 1 1,2,5
187 MUTHUSAMY N. 1 55 4 1 1 1 5 2 2 1 5 2 5 60 1 89 3 3*3 2 2 1 2 1,5
188 CHELLA PERUMAL P. 1 45 3 2 2 2 2 4 1 5 2 2 60 1 124 4 5*2 3 2 2 2 1,2,5
189 NARAYANAN M. 1 60 4 1 2 1 4 2 4 2 5 2 6 60 1 249 3 3*3 2 2 2 1 1,5
190 PALANISAMY A. 1 61 5 1 1 2 2 4 1 5 2 5 60 1 87 2 3*3 2 2 1 1 1,2
191 PETCHIAMMAL 2 63 5 1 1 2 2 4 1 5 2 6 12 1 80 2 2*2 2 2 1 1 1
192
VIGNESH MUTHU 
KUMAR V. DR 1 51 4 3 1 1 2 2 4 1 1 2 5 60 1 100 3 2*2 2 2 1 1 1
193 ARUNACHALAM T. 1 45 3 1 1 2 2 4 1 5 2 6 60 1 130 3 3*2 2 2 1 2 1,2
194 SANGILI A. 1 55 4 1 1 1 3 2 4 1 5 2 6 60
FRE
E 94 2 2*2 2 2 1 1 1
195 BALAMURUGAN K. 1 40 2 1 1 1 5 2 3 1 5 2 4 60 1 88 3 4*4 3 2 1 2 1,5
196 FATHIMA MARY A. 2 55 4 1 1 2 2 2 1 5 1 6 36 1 87 2 3*2 2 2 1 1 1
197 VEERAMMAL R. 2 27 1 1 1 2 2 4 1 5 2 6 24 1 85 2 2*2 2 2 1 1 1,5
198 MANIKANDAN C. 1 22 1 2 1 2 2 4 2 5 2 6 24 1 178 3 2*1 2 2 2 2 1
199 MALYADRI K. 1 60 4 1 2 1 1 2 4 1 5 1 6 60 1 160 4 3*3 2 2 1 1 1
200 HUSSAIN BI 1 45 3 2 1 2 2 1 1 5 2 5 60 1 157 4 3*2 2 2 1 2 1
201 PRABHU C. 1 48 3 1 2 1 3 2 4 1 1 2 6 60 1 80 3 2*4 2 2 1 1 1,5
202 MADASAMY K. 1 55 4 1 1 2 2 4 1 5 2 6 36 1 134 2 2*2 2 2 2 2 1,5
203 MANIMEGALAI M. 2 50 3 1 1 2 2 3 1 5 2 6 24 1 123 2 3*2 2 2 1 2 1
204 SUKUMAR P. 1 45 3 3 2 2 2 4 1 5 2 6 36 1 300 3 4*4 2 2 1 1 1,5
205 MUTHURAMAN C. 1 60 4 2 1 1 2 2 4 1 5 2 1 60 1 120 4 5*5 3 1 1 2 1,2,5
206
KOTA MALAKONDA 
REDDY 1 52 4 5 1 2 2 1 1 5 2 HM 1 120 4 6*4 3 1 1 1 1,2,5
207 RAMACHANDRAN P. 1 55 4 3 2 2 2 1 2 5 2 6 60 1 143 2 3*2 2 2 2 2 1
208 GOVINDARAJAN S. 1 65 5 2 2 2 2 4 1 5 2 FCF 1 146 4 5*5 2 2 1 1 1,2,5
209 NOORJAHAN H. 2 34 2 1 1 1 1 2 4 1 5 2 6 36 1 207 3 4*3 2 2 1 2 1,2
210 MOHAN R. 1 50 3 3 1 2 2 4 1 5 2 HM 1 158 4 5*4 3 1 1 2 1,2
211 GOPINATH K. 1 56 4 2 1 2 2 2 1 5 1 6 12 1 130 1 3*3 2 2 1 1 1
212 AMIRTHAM S. 2 50 3 2 2 2 2 4 1 5 2 6 24 1 117 2 3*2 2 2 2 2 1
213 SULOCHANA K 2 40 2 1 2 1 2 2 1 1 5 2 6 60 1 125 2 4*4 3 2 1 2 1,5
214 RASU K. 1 56 4 1 2 2 2 4 1 5 1 6 60 1 115 3 4*3 2 2 1 1 1,5
215 MANICKAM M 1 50 3 1 2 2 2 4 1 5 2 6 24 1 125 2 3*2 2 2 1 1 1
216 PANJAVARNAM R. 2 60 4 1 2 1 3 2 1 2 5 2 6 60 1 100 3 4*4 2 2 2 1 1,5
217 LAKSHMI S. 2 40 2 1 1 2 2 4 1 5 2 5 60 1 110 3 3*2 2 2 1 1 1
218 VALLIAPPAN P. 1 51 4 2 2 2 2 4 1 5 2 6 60 1 118 2 3*3 2 2 1 2 1
219 MURUGAN S. 1 70 5 2 1 1 1 2 4 1 5 2 HM 1 84 4 5*5 3 1 1 2 1,2,5
220 SOUNDARAJAN K. 1 65 5 1 1 2 2 2 1 5 2 6 60 1 84 3 3*3 2 2 1 2 1,2
221 PALANIAMMAL 2 52 4 1 1 2 2 4 1 5 2 6 9 1 95 2 2*2 2 2 1 1 1
222 CHINNAMMAL V. 2 42 3 1 1 1 3 2 4 1 5 2 6 36 1 120 2 3*2 2 2 1 1 1,5
223 POUN M. 2 60 4 2 2 2 2 3 1 5 2 6 9 1 82 2 2*2 2 2 2 2 1
224 ANTONY DOSS A. 1 40 2 1 2 2 2 4 1 5 2 6 60 1 117 2 3*3 2 2 1 2 1,3
225 KALIYATHAL K. 2 55 4 2 2 2 2 1 2 5 1 5 60 1 97 3 3*3 2 2 1 1 1
226 VIJAYAMMA 2 54 4 1 1 1 2 2 4 1 1 2 HM 1 84 4 5*4 3 1 1 1 1,2,5
227 VALLIAMMAL K. 2 53 4 2 2 2 2 4 1 5 2 6 60 1 90 2 3*3 2 2 1 2 1
228 MARIAPPAN P. 1 55 4 1 1 2 2 2 1 5 1 6 18 1 151 2 3*2 2 2 1 1 1
229 VIJAYALAKSHMI A. 2 32 2 3 2 2 2 1 1 5 2 6 36 1 86 3 3*2 2 2 1 2 1,5
230 VEL MURUGAN 1 23 1 1 2 1 1 2 2 1 5 2 6 24 1 106 2 2*2 2 2 2 1 1,5
231 PALANISAMY V. 1 60 4 1 2 2 2 4 1 5 2 6 36 1 97 2 2*3 2 2 1 1 1,5
232 MURASOLI R. 1 42 3 2 1 2 2 4 1 5 2 FCF 1 81 4 6.5*3.5 3 1 1 2 1,2,5
233 POTTU M. 2 44 3 1 2 1 3 2 4 1 5 2 HM 1 80 3 6*7 3 1 1 2 1,2,5
234 RAYAPPAN S. 1 52 4 3 1 1 6 2 2 2 5 2 6 60 1 120 2 2*2 2 2 1 1 1,5
235 MEENA R. 2 55 4 2 2 2 2 4 1 5 2 5 60 1 172 2 3*4 2 2 1 1 1,2
236 SUBBULAKSHMI S. 2 45 3 1 1 1 5 2 4 1 5 2 HM 1 145 4 6*4 3 2 2 2 1,2,5
237 VENKATAIAH P. 1 62 5 1 1 2 2 1 1 5 2 6 24 1 200 2 2*2 2 2 1 2 1,2
238 MUSALAIAH V. 1 55 4 3 1 2 2 4 1 5 2 6 60 1 114 2 2*3 2 2 1 1 1,5
239
SUBRAMANIYAM 
ACHARI K. 1 50 3 1 1 1 4 2 4 1 5 2 6 12 1 120 1 1*1 2 2 1 1 1
240 MURUGATHAL V. 2 60 4 1 2 2 2 1 2 5 2 6 60 1 150 2 3*3 2 2 1 2 1,5
241 MARIYA AROCKIAM K. 2 50 3 1 1 1 1 2 4 1 4 1 PL 1 100 4 5*4 4 1 1 1 1,2,5
242 THAYAMMAL C. 2 62 5 1 2 2 2 2 1 5 2 5 60 1 250 3 3*3 2 2 1 1 1,5
243 DHANALAKSHMI K. 2 27 1 1 2 2 2 3 1 5 2 5 60 1 178 3 3*2 2 2 1 2 1
244 PANDIAN M. 1 40 2 2 1 1 2 2 4 1 5 1 5 60 1 190 4 4*4 2 2 2 2 1,5
245
DAGGUPATI 
SUBBAIAH 1 60 4 3 2 2 2 4 1 5 2 5 60 1 187 2 5*3 3 2 1 1 1,5
246 SRIDHAR R. 1 50 3 1 1 2 2 4 1 5 2 6 60 1 112 2 4*3 2 2 1 1 1,2
247
BOPPANA CHINA 
VENKATESWARLU 1 55 4 1 2 1 3 2 1 2 5 2 6 36 1 170 4 2*2 2 2 1 1 1
248 CHELLATHAL K. 2 62 5 1 2 2 2 4 1 5 2 6 36 1 98 3 2*2 2 2 1 1 1
249 NATESAPILLAI T. 1 64 5 1 2 1 1 2 2 1 5 2 6 24 1 104 2 2*2 2 2 1 1 1
250 SANKARALINGAM I. 1 60 4 1 2 2 2 4 1 5 2 6 60 1 78 3 4*2 2 2 1 1 1,2
251 CHINNAPILLAI R. 2 50 3 1 1 2 2 4 1 5 2 6 60 1 86 2 2*2 2 2 1 1 1
252 CHINNAMMAL S. 2 52 4 1 1 2 2 4 1 5 2 6 18 1 90 2 2*1 2 2 1 2 1
253 KUMAR M. 1 22 1 4 1 1 1 2 4 1 5 2 6 36 1 98 3 2*2 2 2 1 1 1,5
254 AYYAKALAI 1 60 4 2 2 2 2 1 1 5 2 6 36 1 186 3 2*3 2 2 1 1 1,5
255 KATHAMMAL N. 2 55 4 3 2 2 2 4 2 5 2 HM 1 80 4 5*5 3 1 1 2 1,2,5
256 NAGARAJ R. 1 40 2 1 2 2 2 4 1 5 2 6 60 1 86 2 2*3 2 2 1 2 1,2
257 VIJAYALAKSHMI B. 2 52 4 1 1 1 2 2 4 1 5 1 5 60 1 124 3 3*3 2 2 1 2 1,5
258 SELVARAJ 1 50 3 1 1 2 2 3 1 5 2 2 60 1 115 4 4*4 3 2 2 1 1,2,5
259 RAJENDRAN T. 1 45 3 1 1 1 3 2 2 1 1 2 PL 1 82 4 5*6 3 2 1 2 1,2,5
260 PANJAVARNAM R. 2 55 4 1 2 2 2 4 1 5 1 1 60 1 117 4 4*6 3 1 1 1 1,2,5
261
SENTHAMARAI 
KANNAN R. 1 42 3 2 1 1 1 2 4 1 5 2 6 60 1 97 4 3*3 2 2 1 1 1,2
262 PERUMAL K. 1 47 3 1 2 2 2 4 1 5 2 1 60 1 84 4 5*4 3 2 1 2 1,2,5
263 SEETHAIYAMMAL R. 2 52 4 1 1 2 2 4 1 5 2 6 36 1 90 2 3*2 2 2 1 2 1,5
264 IBRAHIM SHA S. 1 59 4 1 2 1 3 2 1 2 5 2 6 12 1 151 2 2*1 2 2 1 1 1
265 NAGAMMA N. 2 62 5 1 1 2 2 4 1 5 2 6 24 1 86 2 1*1 2 2 1 1 1
266 MANI R. 1 64 5 1 2 2 2 4 1 5 2 1 60 1 106 4 6.5*3.5 3 2 1 1 1,2,5
267 RAVICHANDRAN 1 58 4 2 2 2 2 1 1 5 2 6 60 1 97 2 3*3 2 2 1 1 1,2
268 ARUMUGAM A. 1 50 3 3 2 2 2 4 1 5 2 6 18 1 81 3 1*1.5 2 2 1 1 1
269 DHASTHAGIRI G. 1 60 4 2 1 1 2 2 4 2 5 2 6 36 1 80 2 3*3 2 2 1 1 1
270 TAJ NISHA.H 2 30 1 1 2 2 2 1 1 5 2 6 24 1 72 2 2*2 2 2 1 1 1,5
271
POLA SETTI 
KOTTESWARA RAO 1 61 5 1 1 2 2 4 1 5 2 6 60 1 80 2 5*6 3 2 1 2 1,5
272 MURUGANATHAN 1 52 4 1 1 2 2 4 1 5 2 HM 1 115 4 6*6 3 1 2 2 1,2,5
273 THIRUMURUGAN T. 1 50 3 1 1 1 1 2 4 1 5 1 6 60 1 118 3 3*3 2 2 2 1 1,5
274 MUTHURAJ A. 1 55 4 1 2 2 2 4 1 5 2 6 18 1 130 1 2*1 2 2 1 1 1
275 NAMBURANI P. 2 45 3 1 1 2 2 3 1 5 2 6 36 1 144 2 2*2 2 2 1 2 1,5
276 DHANALAKSHMI M. 2 60 4 2 2 2 2 4 2 5 1 6 18 1 180 1 2*3 2 2 1 1 1,5
277 SEENIVASAN T. 1 40 2 2 1 1 3 2 4 1 5 2 6 24 1 120 2 2*1 2 2 1 2 1
278 RABIYA M. 2 30 1 2 2 2 2 4 1 5 2 6 60 1 114 3 3*3 2 2 1 1 1,2
279 IRULRAJA P. 1 52 4 1 1 1 3 2 2 1 5 2 6 36 1 100 2 2*2 2 2 1 1 1,5
280 MUNIAMMAL K. 2 44 3 1 2 1 3 2 4 1 5 2 HM 1 82 4 6*5 3 1 1 2 1,2,5
281 MOOKKAMMAL 2 56 4 1 2 2 2 4 1 5 2 6 60 1 117 2 3*3 2 2 1 2 1,2
282 NEELA MEGAM M. 1 34 2 1 2 1 1 2 4 1 5 2 6 18 1 97 2 3*3 2 2 1 1 1
283 KADIRI NAGAMMA 2 59 4 1 1 2 2 2 1 5 2 6 36 1 84 3 3*3 2 2 1 1 1,3
284 ANDAL 2 57 4 1 1 2 2 4 2 5 2 PL 1 90 4 5*6 3 1 1 2 1,2,5
285 SIVARAMAN K. 1 60 4 1 1 1 3 2 4 1 5 2 HM 1 151 4 5*4 3 1 1 1 1,2,5
286 MURUGAIAH 1 55 4 1 1 2 2 3 1 5 2 6 60 1 86 3 3*2 2 2 1 1 1,2
287 ELUMALAI A. 1 50 3 1 1 2 2 4 1 5 2 5 60 1 106 4 4*4 2 2 2 1 1,2
288 RAMASAMY V. 1 44 3 1 2 2 2 1 1 5 2 5 60 1 97 2 4*3 2 2 1 1 1,5
289 KANNADASAN S. 1 60 4 1 1 1 2 2 4 1 1 1 PL 1 82 4 6*7 3 2 1 2 1,2,5
290 PARIMALA 2 38 2 2 2 2 2 4 1 5 2 6 60 1 117 2 4*4 3 2 1 1 1,2
291 ESWARI V. 2 45 3 1 1 2 2 4 1 5 2 6 60 1 97 3 3*3 2 2 1 1 1,5
292 BALAKRISHNAN D. 1 60 4 1 2 1 3 2 4 1 5 1 2 60 1 84 2 4*4 2 2 1 2 1,2,5
293 MALAR KODI J. 2 54 4 1 1 1 4 2 1 2 5 2 PL 1 90 4 5*5 3 2 1 2 1,2,5
294 KALIAMAML P. 2 50 3 1 2 2 2 4 1 5 2 6 9 1 151 1 1*1 2 2 1 2 1
295 MATHAMMAL V. 2 65 5 1 2 2 2 1 1 5 2 6 36 1 86 3 2*2 2 2 1 1 1
296 MARIAMMAL S. 2 55 4 1 2 2 2 4 1 5 2 6 24 1 106 2 3*2 2 2 1 2 1,5
297 PALANISAMY 1 48 3 2 1 1 1 2 4 1 5 2 6 24 1 97 2 4*4 2 2 1 1 1,5
298 MAYANDI R. 1 58 4 2 1 1 6 2 2 1 5 2 6 60 1 81 3 5*3 3 2 1 1 1,2
299 MAHALINGAM M. 1 57 4 3 1 2 2 4 2 5 2 HM 1 80 4 6*6 3 1 1 2 1,2,5
300 MAHALINGAM M. 1 37 2 1 1 2 2 4 2 5 2 6 24 1 110 2 2*1 2 2 1 1 1,5
301 NAGAMMA K. 2 60 4 1 2 1 3 2 4 1 5 2 6 12 1 143 1 1*1 2 2 1 1 1
302 KANNAN D. 1 48 3 1 2 2 2 4 2 5 2 6 18 1 146 2 1.5*1.5 2 2 1 2 1
303 KALIMUTHU M. 1 57 4 1 2 1 4 2 4 1 5 2 HM 1 207 4 5*3 4 1 1 2 1,2,5
304 NITHISH KUMAR S. 1 46 3 1 2 2 2 2 1 5 2 6 60 1 158 4 3*3 2 2 1 1 1,5
305 LAKSHMI R. 2 60 4 2 1 1 1 2 4 1 4 2 6 18 1 130 2 2*2 2 2 1 2 1
306 SASTIVEL M.A. 1 40 2 2 1 2 2 4 1 5 2 6 36 1 117 2 2*2 2 2 1 2 1,2
307 RAJU A. 1 64 5 1 2 2 2 4 1 5 1 6 18 1 125 2 2*2 2 2 1 1 1
308 AYOTHI RAMAN K. 1 51 4 1 1 2 2 2 1 5 2 6 12 1 115 2 2*1 2 2 1 1 1
309 BALAMURUGAN G. 1 42 3 1 2 1 3 2 2 1 5 2 HM 1 125 4 6*4 3 1 1 2 1,2,5
310 PETCHIAMMAL 2 60 4 1 2 2 2 4 2 5 1 6 60 1 100 3 4*4 3 2 1 1 1,5
311 SUBBAIAH M 1 40 2 1 2 2 2 4 1 5 2 6 18 1 110 2 3*2 2 2 1 1 1
312 NALLAMMAL .R 2 55 4 2 1 2 2 3 1 5 2 6 36 1 118 3 3*3 2 2 1 1 1
313 SEENIAMMAL K. 2 53 4 1 1 1 2 2 3 1 2 2 3 60 1 84 4 4*5 2 2 1 1 1,5
314 DEIVANAI 2 59 4 1 1 2 2 4 2 5 2 6 24 1 84 2 2*2 2 2 2 2 1
315 LAKSHMI J. 2 57 4 1 1 2 2 4 1 5 2 6 60 1 95 2 2*2 2 2 1 2 1,5
316 VADIVEL P. 1 45 3 1 2 1 6 2 4 2 5 2 6 36 1 120 2 3*3 2 2 1 1 1,5
317 MADHUSUDHAN 1 49 3 1 2 2 2 4 1 5 1 3 60 1 82 3 5*6 3 2 1 1 1,2,5
318 RASU E. 1 51 4 1 2 1 3 2 4 1 5 2 6 60 1 117 3 2*2 2 2 1 2 1,2
319 SANGEETHA R. 2 26 1 1 1 2 2 4 1 5 2 6 18 1 97 2 2*1 2 2 1 2 1,5
320 SUBBARAYUDU 1 44 3 2 2 1 1 2 4 1 5 2 6 36 1 143 2 4*3 2 2 2 1 1
321 BOSE 1 60 4 3 2 2 2 1 1 5 2 1 60 1 146 4 5*5 3 1 1 1 1,2,5
322 MURUGATHAL M. 2 55 4 1 2 1 2 2 2 1 5 2 6 60 1 207 3 3*3 2 2 1 2 1,3
323 ALAGAN L. 1 45 3 1 2 2 2 4 1 5 2 3 60 1 158 3 4*4 2 2 1 1 1,2
324 NATARAJAN R. 1 40 2 1 1 2 2 3 2 5 2 6 18 1 130 1 1*1 2 2 1 1 1
325 PAKKIRAMMA 2 60 4 1 1 1 4 2 4 1 5 2 HM 1 117 4 5*5 3 2 1 2 1,2,5
326 THATHAR GOUNDAR 1 35 2 1 2 2 2 4 1 5 2 6 60 1 125 3 2*2 2 2 1 2 1
327 PITCHAIAMMAL G. 2 54 4 2 1 1 2 2 4 1 5 2 6 18 1 115 2 2*1 2 2 1 1 1
328 GANGA BHAVANI 2 42 3 1 2 1 5 2 4 1 5 2 6 36 1 125 2 2*2 2 2 1 1 1
329 PONNAMMAL R. 2 62 5 1 2 2 2 1 1 5 2 6 18 1 100 2 1*1 2 2 1 1 1
330 BALKEES BEEVI 2 55 4 1 2 2 2 4 1 5 2 6 12 1 110 2 1*2 2 2 1 1 1
331 SUNTHARI 2 49 3 1 1 1 1 2 4 1 5 1 HM 1 118 4 5*5 3 1 1 1 1,2,5
332 CHINNA SUBBAIAH T. 1 52 4 1 1 1 6 2 4 2 5 2 6 60 1 84 3 3*3 2 2 1 1 1,2
333 AMSATHAL K. 2 48 3 2 1 2 2 1 1 5 2 6 18 1 84 2 2*2 2 2 1 1 1
334 MURUGAN 1 55 4 1 1 2 2 4 1 5 1 6 36 1 95 3 2*3 2 2 2 2 1,2
335 THANGARAJ A. 1 65 5 2 2 1 2 2 4 2 5 2 6 18 1 120 2 2*1 2 2 1 1 1
336 ANEESH SIVANANDAN 1 28 1 3 2 2 2 4 2 5 2 6 24 1 82 2 2*2 2 2 1 1 1
337
BALAYAPALLI 
SUJATHA 2 24 1 1 2 2 2 4 1 5 2 6 60 1 117 2 2*2 2 2 1 1 1,5
338 PAPPAYEE 2 45 3 1 2 2 2 4 2 5 2 6 36 1 97 2 2*2 2 2 1 2 1,5
339 KUPPUSWAMI C. 1 62 5 4 2 1 1 2 4 1 1 2 HM 1 84 4 5*6 3 2 1 2 1,2,5
340 RAVI D. 1 40 2 2 2 2 2 4 1 5 2 6 60 1 143 2 2*2 2 2 1 1 1,2
341 SURIYAKALA K 2 60 4 2 2 2 2 4 1 5 1 6 18 1 146 3 1*1 2 2 1 1 1,2
342
SANGARA 
NARAYANAN S. 1 55 4 3 1 1 1 2 4 1 5 2 6 36 1 207 2 2*2 2 2 1 2 1
343 PENCHALAIAH 1 54 4 1 1 2 2 4 1 5 2 1 60 1 158 4 4*5 3 1 1 2 1,2,5
344 THANGA RAJ 1 51 4 1 2 2 2 2 1 5 2 4 60 1 130 4 4*4 2 2 1 1 1,2,5
345 KRISHNAVENI S. 2 35 2 1 1 1 3 2 4 1 5 2 6 24 1 117 2 2*2 2 2 1 2 1,2
346 MUTHUSAMY M. 1 46 3 1 2 2 2 4 1 5 2 6 60 1 125 2 2*2 2 2 1 2 1,2
347 PAPPA R. 2 53 4 1 2 2 2 4 1 5 2 PL 1 115 4 5*4 3 1 1 1 1,2,5
348 MURUGAN V. 1 42 3 2 2 1 1 2 1 1 5 2 6 24 1 125 2 2*2 2 2 2 1 1,2
349 ASWATHI KIRUBAA 2 45 3 1 1 2 2 4 1 5 2 6 60 1 100 3 3*3 2 2 1 1 1,2
350 PANCHAVARNAM 2 55 4 1 1 1 4 2 4 2 5 2 5 60 1 110 3 3*3 2 2 1 1 1
351 LAKSHMI A 2 60 4 1 1 2 2 3 1 5 2 6 60 1 118 2 3*2 2 2 1 1 1,2
352 BYROS KHAN R 1 50 3 1 1 1 1 2 4 1 5 2 HM 1 84 4 5*5 3 1 1 2 1,2,5
353 JANGAM REDDY 1 35 2 1 2 2 2 4 2 5 2 6 60 1 84 3 2*2 2 2 1 1 1
354 ALAGAMMAL 2 54 4 2 2 2 2 4 2 5 2 6 18 1 95 2 2*2 2 2 1 2 1
355 ANANTHAN R. 1 44 3 1 2 2 2 4 1 5 1 6 36 1 120 2 2*2 2 2 1 1 1
356 MUTHAMMAL M. 2 60 4 4 2 1 1 2 4 2 5 2 6 24 1 82 2 2*1 2 2 1 1 1,2
357 CHANDRASEKARAN K. 1 42 3 1 2 2 2 4 1 5 2 6 60 1 117 3 2*2 2 2 1 1 1
358 VIVEKANANDAN G. 1 62 5 1 2 2 2 4 1 5 1 5 60 1 97 3 2*3 2 2 1 2 1,5
359 AJITH S. 1 25 1 4 1 2 2 4 1 5 2 2 60 1 143 4 3*3 2 2 1 2 1,5
360 SUBBAMMA 2 46 3 1 1 1 1 2 4 1 5 2 6 60 1 146 3 3*3 2 2 1 1 1,2
361 MURUGESAN K 1 55 4 2 2 2 2 4 1 5 2 6 18 1 207 2 2*2 2 2 1 1 1
362 DHANAPALAN P. 1 45 3 2 1 2 2 4 1 5 2 6 36 1 158 2 2*2 2 2 2 2 1
363 ABISHEK M. 1 60 4 3 2 2 2 4 1 5 2 6 24 1 130 2 2*1 2 2 2 1 1
364 RASATHI 2 40 2 1 2 1 1 2 1 1 5 2 6 24 1 117 2 2*2 2 2 1 1 1,5
365 THANGAM G. 2 65 5 1 2 2 2 4 1 5 1 6 60 1 125 2 3*2 2 2 1 2 1,5
366 RAMAR P. 1 51 4 1 1 2 2 3 1 5 2 6 60 1 115 3 3*1.5 2 2 1 2 1,2
367 MURUGAPPAN 1 45 3 1 1 1 4 2 4 1 5 2 6 24 1 125 3 2*2 2 2 1 1 1
368 SUBRAMANI R. 1 60 4 1 1 2 2 4 1 5 2 6 60 1 100 2 3*2 2 2 1 1 1,2
369 RAM THAI 2 67 5 2 1 1 1 2 2 2 5 2 5 60 1 110 3 3*2 2 2 1 1 1,5
370 THANKA R. 1 55 4 2 2 2 2 4 1 5 2 6 36 1 118 2 2*2 2 2 1 1 1,5
371 ALAGUTHAI.R 2 60 4 1 2 2 2 4 1 5 2 HM 1 84 4 5*5 3 2 1 1 1,2,5
372 MUTHU MURUGAN K. 1 51 4 1 2 2 2 1 2 5 2 6 60 1 84 2 2*2 2 2 1 1 1
373 PITCHAI A. 1 55 4 1 2 1 1 2 4 2 5 2 4 60 1 95 4 3*5 2 2 1 1 1,2,5
374 AMEENA J. 2 27 1 1 2 2 2 4 1 5 2 6 36 1 120 2 2*2 2 2 1 2 1
375 RAVI K. 1 46 3 1 2 2 2 4 2 5 2 6 24 1 82 2 2*3 2 2 1 1 1
376
YANAMALA LAKSHMI 
NARAYANA 2 55 4 2 2 2 2 2 1 5 2 6 60 1 117 3 3*3 2 2 2 1 1,5
377 SAKTHIVEL M. 1 35 2 1 1 1 2 2 4 1 2 2 5 60 1 97 2 3*3 2 2 1 1 1,5
378 LAKSHMI DEVI 2 45 3 1 1 2 2 4 1 5 2 6 60 1 84 2 2*2 2 2 1 2 1
379 MATHAVANAI P. 2 55 4 1 2 2 2 4 1 5 1 6 60 1 143 2 3*3 2 2 1 2 1,5
380 RAJAMANICKAM 1 60 4 1 1 1 1 2 4 1 5 2 6 18 1 146 1 1*1 2 2 1 1 1
381 RATHINAM S. 2 50 3 1 2 2 2 4 1 5 2 6 36 1 207 3 2*2 2 2 1 1 1,2
382 JEYA PRAKASH R. 1 36 2 3 2 1 6 2 2 1 5 1 6 24 1 158 2 2*2 2 2 1 2 1,2
383 ANANDHARAJ L. 1 56 4 2 2 2 2 1 1 5 2 6 24 1 130 2 2*2 2 2 1 1 1
384 RAMANAIAH 1 48 3 2 1 1 1 2 4 1 5 2 6 60 1 117 2 2*1 2 2 1 1 1,5
385 SAMI 1 59 4 3 1 2 2 4 1 5 2 6 60 1 125 3 3*2 2 2 1 2 1
386 TAMILARASAN P. 1 44 3 1 1 2 2 4 1 5 2 6 24 1 115 2 2*2 2 2 1 2 1,2
387 ALAGU VEL 1 36 2 1 1 2 2 4 1 5 2 6 60 1 125 2 2*2 2 2 1 1 1
388 SHANMUGARAJ S. 1 54 4 1 2 1 1 2 2 2 5 2 5 60 1 100 3 3*3 2 2 1 1 1,5
389 MEENA S. 2 48 3 1 2 2 2 1 1 5 1 6 18 1 110 1 2*1 2 2 1 1 1
390 AYYAKANNU V 1 57 4 1 2 2 2 4 1 5 2 HM 1 118 4 5*5 3 1 2 2 1,2,5
391 MOHAN RAJ 1 50 3 1 2 2 2 4 2 5 2 6 60 1 84 4 3*2 2 2 1 1 1
392 GOVINDHARASU G. 1 55 4 1 1 1 1 2 2 2 5 2 6 18 1 84 2 2*2 2 2 2 1 1
393 SILVAR STAR S 1 40 2 1 1 2 2 4 1 5 2 6 36 1 95 2 4*5 2 2 1 1 1,5
394
BANDISELLA 
BRAMAIAH 1 63 5 1 2 2 2 4 2 5 2 6 24 1 120 2 2*2 2 2 1 2 1
395 YOGESHWARAN 1 52 4 1 1 2 2 4 1 5 2 6 60 1 82 3 2*2 2 2 1 1 1
396 PANCHAVARNAM 2 50 3 2 2 1 1 2 3 1 5 2 5 60 1 143 3 3*2 2 2 1 1 1,5
397 IRUDHAYARAJ S. 1 55 4 1 2 2 2 4 1 5 2 PL 1 146 4 5*6 3 1 1 2 1,2,5
398 VADIVEL C. 1 32 2 2 2 2 2 4 1 5 2 6 60 1 207 3 2*3 2 2 1 2 1
399 ALAGAMMAL C. 2 54 4 1 1 1 6 2 4 1 5 2 6 18 1 158 3 2*1 2 2 1 2 1
400 MURUGESWARI R. 2 58 4 1 1 1 2 2 1 1 5 2 6 36 1 130 2 2*2 2 2 1 1 1,5
401 GURUMURUGAN B. 1 55 4 1 1 2 2 4 1 5 2 6 9 1 117 1 1*1 2 2 1 1 1
402 CHINNAMMAL R. 2 25 1 1 2 1 4 2 1 2 5 2 6 24 1 125 2 2*2 2 2 1 1 1
403
SHAIK KHADAR 
MASTAN 1 60 4 1 2 2 2 4 1 5 1 6 12 1 115 2 2*1 2 2 1 2 1
404 LAKSHMI M. 2 50 3 2 2 1 1 2 4 1 5 2 6 60 1 125 3 2*2 2 2 2 1 1,5
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1 CHANDRA DEVI 6 60 1,2 2 2 6 24 1,2 2 2 6 24 3*3 1 1
2 PIDARI 6 36 1 2 2 6 18 1 2 2 6 18 1*2 1 1
3 PANJAVARNAM 1 60 1,2,5 2 2 1 60 1,2,5 2 2 1 60 6*6 1 1
4 CHANDRAN A 6 9 1 1 2 6 9 1 1 2 6 9 1*2 1 1
5 CHINNA 6 60 1,5 2 2 6 24 1,5 2 2 6 24 3*3 1 1
6 BALASUBRAMANI S 1 60 1,2,5 4 2 1 1 1 60 1,2,5 4 1 1 60 0 4 0
7 NAGAMMA 6 36 1,5 2 2 6 36 1,5 2 2 6 36 4*3 1 1
8 ANWAR BATCHA 6 24 1 2 2 6 9 1 2 2 6 9 1*2 1 1
9 VALLIAMMAI G 6 9 1 1 2 6 9 1 1 2 6 9 1*2 1 1
10 KALIAMMAL S 6 60 1,5 2 2 6 36 1,5 2 2 6 24 3*3 1 1
11 PRITHVIRAJ C 5 60 1 2 2 6 36 1 2 2 6 18 2*3 1 1
12 MUNIYASAMY 3 60 1,2 2 2 6 60 1,2 2 2 6 60 5*5 1 1
13 VEERANAN A 6 60 1,5 2 2 6 60 1,5 2 2 6 36 2*3 1 1
14 SUBBAIAH P 6 36 1 2 2 6 18 1 2 2 6 18 1*2 1 1
15 SEENI S 6 12 1,5 2 2 6 9 1,5 2 2 6 9 1*2 1 1
16 MURUGAN M 6 60 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
17 RACKKI A 1 60 1,5 2 2 1 60 1,5 2 1 1 1 60 0 3 0
18 JILANI PL 1,2 4 1 1 PL 1,2 4 1 PL 0 4 0
19 RAJU S 4 60 1,2 3 2 6 60 1,2 3 2 6 60 5*5 1 1
20 CHINNAIAH D 6 36 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
21 ALAGARSAMY 6 60 1,2,5 2 2 6 36 1,2,5 2 2 6 36 4*4 1 1
22 MALLIKA C 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
23 UMADEVI 6 9 1 1 2 6 9 1 1 2 6 9 1*2 1 1
24 POOPANDI 6 6 1 1 2 6 6 1 1 2 6 6 1*1 1 1
25 SUKHIBAI 6 60 1,5 2 2 6 24 1,5 2 2 6 24 2*3 1 1
26 CHINNAPONNU 6 60 1,5 2 2 6 36 1,5 2 2 6 36 4*4 1 1
27 CHINNAKARUPPAN 6 12 1 2 2 6 9 1 2 2 6 9 2*1 1 1
28 SAIKUMAR K 6 60 1,5 2 2 6 60 1,5 2 2 6 60 5*6 1 1
29 MUTHUSAMY P HM 1,2,5 4 2 1 1 HM 1,2,5 4 2 HM 0 4 0
30 HARINATH M 6 60 1,5 2 2 6 24 1,5 2 2 6 24 5*5 1 1
31 VIGNESH M 6 24 1 2 2 6 24 1 2 2 6 24 3*3 1 1
32 KARUPPATHAL N 1 60 1,5 2 2 1 60 1,5 2 2 1 60 6*6 1 1
33 MUNIYAPPAN R 6 9 1 2 2 6 9 1 2 2 6 9 2*2 1
34 MADASAMY M HM 1,2 4 1 1 HM 1,2 4 1 HM 0 4 0
35 CHINNAIAH P L 6 60 1 2 2 6 24 1 2 2 6 24 2*2 1 1
36 RAJIYA BEGUM A 6 9 1 1 2 6 6 1 1 2 6 6 1*1 1 1
37 THIRUMALAI V 6 12 1,5 2 2 6 9 1,5 2 2 6 9 2*2 1 1
38 MUTHURAJ A PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
39 RUCKMANI P 6 36 1 2 2 6 36 1 2 2 6 36 3*3 1 1
40 KANNAN A 6 12 1 2 2 6 12 1 2 2 6 12 2*2 1 1
41 MANI M 6 6 1 1 2 6 6 1 1 2 6 6 1*1 1 1
42 VENKATA SUBBAREDDY 6 24 1 2 2 6 24 1 2 2 6 24 3*2 1 1
3 WEEKS 1 MONTH 3 MONTHS
43 PONNAN T 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
44 SHANTHI S 6 60 1,5 2 2 6 36 1,5 2 2 6 36 2*3 1 1
45 SHANTHI S 6 24 1 2 2 6 12 1 2 2 6 12 2*2 1 1
46 MAYILATHAL 6 36 1,5 2 2 6 18 1,5 2 2 6 18 4*3 1 1
47 NAGARAJU 6 18 1 2 2 6 12 1 2 2 6 12 2*2 1 1
48 MARIAMMAL K 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
49 ESWARAIAH N 6 60 1 2 2 6 24 1 2 2 6 24 3*2 1 1
50 RAMANA G 6 36 1 2 2 6 36 1 2 2 6 36 3*2 1 1
51 MARIAMMAL R 6 60 1,5 3 2 6 60 1,5 3 2 6 60 3*2 1 1
52 MUTHU K 6 60 1,5 2 2 6 60 1,5 2 2 6 60 3*3 1 1
53 SUBRAMANIAN S 6 60 1,5 2 2 6 60 1,5 2 2 6 60 4*4 1 1
54 SUBRAMANI V 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
55 SURESH KUMAR M 6 36 1 3 2 6 18 1 3 2 6 18 2*2 1 1
56 RAMU U 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
57 SINGARAVEL P 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
58 SIVAPPURAJA T 6 9 1,2 2 2 6 9 1,2 2 2 6 9 2*1 1 1
59 CHINNAMMAL E HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
60 VENKATALAKSHMI 6 36 1 2 2 6 24 1 2 2 6 24 2*2 1 1
61 PENCHALAIAH PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
62 AMARAVATHI K 6 12 1,2 2 2 6 9 1,2 2 2 6 9 2*2 1 1
63 JEYANTHI P 6 60 1,5 2 2 6 24 1,5 2 2 6 24 3*2 1 1
64 SANKAR V 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*1 1 1
65 MOHAN V 6 36 1,5 2 2 6 36 1,5 2 2 6 36 2*2.5 1 1
66 MURUGAN K 6 60 1,2,5 1 2 6 60 1,2,5 1 2 6 60 2*3 1 1
67 MONICKA 6 18 1 2 2 6 18 1 2 2 6 18 2*1 1 1
68 MUTHULAKSHMI S 6 60 1,2 3 2 6 36 1,2 3 2 6 36 2*2 1 1
69 GANESAN N 6 9 1,5 1 2 6 9 1,5 1 2 6 9 2*1 1 1
70 PAPPATHI A 5 60 1,5 3 2 6 60 1,5 3 2 6 60 2*2 1 1
71 UNNAMALAI 6 12 1,5 2 2 6 9 1,5 2 2 6 9 2*2 1 1
72 MUNIYAMMAL M 6 60 1,2,5 2 2 6 60 1,2,5 2 2 6 60 2*2 1 1
73 TAMILSELVI U 6 6 1 1 2 6 6 1 1 2 6 6 2*1 1 1
74 ARUNA M 6 9 1,5 1 2 6 9 1,5 1 2 6 9 1*1 1 1
75 VADIVEL K 5 60 1,5 2 2 6 60 1,5 2 2 6 60 3*2 1 1
76 PANDIYAN M 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
77 NATCHAMMAI C 6 24 1 2 2 6 24 1 2 2 6 24 2*1 1 1
78 IYAPPAN S 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
79 ANTHONI SAMY Y 6 60 1,5 2 2 6 60 1,5 2 2 6 60 2*2 1 1
80 SAHAYA RAJ L 6 24 1,5 2 2 6 12 1,5 2 2 6 12 2*1 1 1
81 MUKILA M 6 60 1 2 2 6 60 1 2 2 6 60 2*2 1 1
82 CHELLADURAI M 6 9 1,2 1 2 6 9 1,2 1 2 6 9 2*2 1 1
83 CHANDRA SEKHAR G 6 9 1 1 2 6 9 1 1 2 6 9 2*1 1 1
84 RUCKMANI P 6 12 1,2,5 2 2 6 12 1,2,5 2 2 6 12 1*1 1 1
85 PALANIVEL K 6 24 1,5 2 2 6 12 1,5 2 2 6 12 2*1 1 1
86 MUNEESWARAN N 6 6 1,2,5 1 2 6 6 1,2,5 1 2 6 6 1*1 1 1
87 SEETHALAKSHMI M 6 24 1 2 2 6 18 1 2 2 6 18 1*1 1 1
88 GOVINDAN V 6 36 1,5 2 2 6 24 1,5 2 2 6 24 2*1 1 1
89 BOOMI V 6 60 1,2,5 2 2 6 36 1,2,5 2 2 6 36 3*2 1 1
90 GOMATHY C HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
91 KARUPPAYEE N 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
92 AMMALU 6 36 1 2 2 6 24 1 2 2 6 24 2*1 1 1
93 ARUL PRAKASH S 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*1 1 1
94 MANI A 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
95 VENKATESH V 6 60 1 2 2 6 36 1 2 2 6 36 2*2 1 1
96 KALIDASS M 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
97 ARUMUGAM P 6 60 1,5 3 2 6 60 1,5 3 2 6 60 2*2 1 1
98 KRISHNAN 6 12 1,2 2 2 6 12 1,2 2 2 6 12 2*2 1 1
99 PITCHAI DEVAR 6 24 1 2 2 6 24 1 2 2 6 24 2*2 1 1
100 KUMAR S 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*1 1 1
101 ARUL DASS D 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
102 PANDI P 6 36 1,2 2 2 6 18 1,2 2 2 6 18 1*2 1 1
103 MURUGESAN K 6 18 1 2 2 6 12 1 2 2 6 12 1*2 1 1
104 MOHAMMED ASMI S 6 24 1 2 2 6 24 1 2 2 6 24 1*1 1 1
105 SEKAR M 6 36 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
106 KASIM G 6 24 1 2 2 6 9 1 2 2 6 9 1*1 1 1
107 ANNAKILI V 6 12 1 2 2 6 12 1 2 2 6 12 2*2 1 1
108 SANKARAN V 6 24 1 2 2 6 24 1 2 2 6 24 1*1 1 1
109 RUTHIRA MOORTHY S 6 60 1,5 2 2 6 36 1,5 2 2 6 36 2*2 1 1
110 KARUKKAVEL I 6 60 1 2 2 6 24 1 2 2 6 24 1*2 1 1
111 MANIKANDAN K 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
112 GOVINDAMMAL K 6 24 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
113 PALANISAMY PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 5 0
114 NAGARAJAN R 6 12 1,5 2 2 6 9 1,5 2 2 6 9 2*2 1 1
115 SEENAIAH V 6 9 1 2 2 6 9 1 2 2 6 9 2*1 1 1
116 DEVDASS S 6 36 1 2 2 6 36 1 2 2 6 36 1*2 1 1
117 MARY LAISHA 6 9 1,5 2 2 6 9 1,5 2 2 6 9 3*2 1 1
118 CHITRA N 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
119 PITCHAI KALAI P 6 24 1,5 2 2 6 24 1,5 2 2 6 24 3*4 1 1
120 RAJANGAM PL 1,2 4 1 1 PL 1,2 4 1 PL 0 4 0
121 ANUSIYA DEVI M 6 12 1 2 2 6 12 1 2 2 6 12 2*2 1 1
122 RAVICHANDRAN P 6 18 1 2 2 6 18 1 2 2 6 18 2*1 1 1
123 MUTHUKUMAR R 5 60 1,5 3 2 5 60 1,5 3 2 5 60 3*4 1 1
124 ARRANGANATHAN R 6 60 1 2 2 6 18 1 2 2 6 18 2*1 1 1
125 SIVAIAH T 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*3 1 1
126 CHINNA DURAI S 6 12 1,2 2 2 6 12 1,2 2 2 6 12 2*2 1 1
127 SAKILA DEVI A 6 60 1,2 2 2 6 60 1,2 2 2 6 60 3*2 1 1
128 PONNAMMAL K 6 9 1,2 2 2 6 9 1,2 2 2 6 9 2*2 1 1
129 ALAGARSAMY S PL 1,2,5 4 2 1 1 PL 1,2,5 4 2 PL 0 4 0
130 PONNANDI V 4 60 1,2,5 3 2 6 60 1,2,5 3 2 6 60 3*3 1 1
131 VINOTH KUMAR I 6 60 1 2 2 6 60 1 2 2 6 60 2*2 1 1
132 JEYA MANI P 6 24 1,2,5 2 2 6 24 1,2,5 2 2 6 24 2*2 1 1
133 MARIAMMAL P 6 36 1 2 2 6 12 1 2 2 6 12 2*2 1 1
134 VIVEKANANTHA S 6 60 1 2 2 6 60 1 2 2 6 60 2*3 1 1
135 GUNASEELAN M 6 36 1,2 2 2 6 18 1,2 2 2 6 18 3*3 1 1
136 RAMANAMMA C 6 18 1,2 2 2 6 9 1,2 2 2 6 9 2*1 1 1
137 PANDIAMMAL K PL 1,2,5 2 1 1 PL 1,2,5 2 1 PL 0 4 0
138 BALAMANI M HM 1,2,5 4 2 1 1 HM 1,2,5 4 2 HM 0 4 0
139 HAJEE AKBAR M 6 12 1,2 2 2 6 9 1,2 2 2 6 9 1*1 1 1
140 PALANISAMY C 6 24 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
141 RAJENDRAN M S 6 60 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
142 BALAMURUGAN S 6 24 1 2 2 6 24 1 2 2 6 24 2*2 1 1
143 SEVAGAN A 6 24 1 2 2 6 12 1 2 2 6 12 2*2 1 1
144 VELAISAMY L 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*3 1 1
145 PANCHABATLA VENU 6 6 1,2 1 2 6 6 1,2 1 2 6 6 1*1 1 1
146 KALYANA SUNDARAM S 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*1 1 1
147 NITHIKUMAR M 6 36 1,5 2 2 6 12 1,5 2 2 6 12 1*1 1 1
148 MURUGAN P 5 60 1 3 2 6 60 1 3 2 6 60 2*3 1 1
149 MUNIYANDI K 6 6 1 1 2 6 6 1 1 2 6 6 1*1 1 1
150 CHELLATHAI PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
151 ALPHONSE MARY S 1 60 1,2,5 3 2 HM 1,2,5 3 2 1 1 HM 0 4 0
152 PALRAJ K 6 12 1 2 2 6 12 1 2 2 6 12 2*2 1 1
153 KATHIRI VEL G 6 12 1 2 2 6 9 1 2 2 6 9 1*1 1 1
154 CHELLATHAI 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
155 VALARMATHI R PL 1,2,5 4 2 1 1 PL 1,2,5 4 2 PL 0 4 0
156 VELAYEE K 6 12 1,2,5 2 2 6 12 1,2,5 2 2 6 12 1*1 1 1
157 VARADHARAJAN K 6 60 1,2 2 2 6 24 1,2 2 2 6 24 2*2 1 1
158 MOHAMED AFRIDI K 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
159 ADHI NARAYANAN CH 1 60 1,2,5 2 2 1 60 1,2,5 2 1 1 1 60 0 4 0
160 LAKSHMI A 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*1 1 1
161 VENKATA RAO Y PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
162 PENCHALAIAH N 6 9 1,2 1 2 6 9 1,2 1 2 6 9 1*1 1 1
163 AJITH M 6 24 1 2 2 6 24 1 2 2 6 24 1*2 1 1
164 INDIRAN C HM 1,2,5 4 2 1 1 HM 1,2,5 4 2 HM 0 4 0
165 NAZEER HUSSAIN S 6 18 1 2 2 6 18 1 2 2 6 18 2*2 1 1
166 CHINNATHAMBI 6 60 1 2 2 6 60 1 2 2 6 60 3*3 1 1
167 SAHAYAMARY A HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
168 JOHN S 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
169 KARUPPAIAH A 6 36 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
170 SWAMINATHAN PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
171 AYYANAR K 6 18 1 2 2 6 12 1 2 2 6 12 1*1 1 1
172 ARUNACHALA THAI 6 36 1 2 2 6 24 1 2 2 6 24 2*1 1 1
173 GANESAN V 6 60 1 2 2 6 60 1 2 2 6 60 3*2 1 1
174 MUTHUPANDI A HM 1,2,5 3 2 HM 1,2,5 3 1 1 HM 0 4 0
175 PERIYASAMY 6 18 1 2 2 6 18 1 2 2 6 18 2*1 1 1
176 MUTHURAMAN K 6 36 1 2 2 6 9 1 2 2 6 9 1*1 1 1
177 MARKKANDAN O 6 18 1 2 2 6 12 1 2 2 6 12 1*1 1 1
178 RAMANA REDDY 6 24 1,2 2 2 6 9 1,2 2 2 6 9 2*1 1 1
179 LALITHA 1 60 1,2,5 2 2 1 60 1,2,5 2 2 1 60 4*5 1 1
180 KRISHNAMMAL A 6 60 1,2 3 2 6 24 1,2 3 2 6 24 2*2 1 1
181 CHINNAMMAL R 6 18 1 2 2 6 12 1 2 2 6 12 1*1 1 1
182 NAGAMMAL V 6 6 1,2 1 2 6 6 1,2 1 2 6 6 1*1 1 1
183 VELLAIAMMAL V 6 36 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
184 AKKINI S. 6 24 1 2 2 6 18 1 2 2 6 18 2*2 1 1
185 BOOMINATHAN M. 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
186 CHELLAMMAL P. HM 1,2,5 3 2 HM 1,2,5 3 2 HM 6*6 1 1
187 MUTHUSAMY N. 5 60 1,5 3 2 6 36 1,5 3 2 6 36 2*3 1 1
188 CHELLA PERUMAL P. HM 1,2,5 4 2 1 1 HM 1,2,5 4 2 HM 0 4 0
189 NARAYANAN M. 6 60 1,5 3 2 6 60 1,5 3 2 6 24 2*2 1 1
190 PALANISAMY A. 6 60 1,2 2 2 6 60 1,2 2 2 6 60 2*3 1 1
191 PETCHIAMMAL 6 12 1 2 2 6 12 1 2 2 6 12 1*2 1 1
192 VIGNESH MUTHU KUMAR V. DR 6 60 1 2 2 6 60 1 2 2 6 60 2*2 1 1
193 ARUNACHALAM T. 6 60 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
194 SANGILI A. 6 60 1 2 2 6 24 1 2 2 6 24 1*2 1 1
195 BALAMURUGAN K. 5 60 1,5 2 2 5 60 1,5 2 2 5 60 3*3 1 1
196 FATHIMA MARY A. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
197 VEERAMMAL R. 6 18 1,5 2 2 6 12 1,5 2 2 6 12 1*2 1 1
198 MANIKANDAN C. 6 24 1 2 2 6 18 1 2 2 6 18 1*1 1 1
199 MALYADRI K. 6 60 1 3 2 6 60 1 3 2 6 60 2*3 1 1
200 HUSSAIN BI 6 60 1 2 2 6 60 1 2 2 6 60 2*2 1 1
201 PRABHU C. 6 36 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1
202 MADASAMY K. 6 36 1,5 2 2 6 12 1,5 2 2 6 12 1*2 1 1
203 MANIMEGALAI M. 6 24 1 2 2 6 24 1 2 2 6 9 2*1 1 1
204 SUKUMAR P. 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
205 MUTHURAMAN C. 1 60 1,2,5 3 2 1 60 1,2,5 3 1 1 1 60 0 4 0
206 KOTA MALAKONDAREDDY HM 1,2,5 3 2 HM 1,2,5 3 2 HM 6*6 1 1
207 RAMACHANDRAN P. 6 60 1 2 2 6 36 1 2 2 6 36 2*2 1 1
208 GOVINDARAJAN S. 1 60 1,2,5 2 2 1 60 1,2,5 2 2 1 1 1 60 0 4 0
209 NOORJAHAN H. 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*2 1 1
210 MOHAN R. HM 1,2 3 2 HM 1,2 3 1 1 HM 0 4 0
211 GOPINATH K. 6 9 1 2 2 6 9 1 2 2 6 9 2*2 1 1
212 AMIRTHAM S. 6 18 1 2 2 6 18 1 2 2 6 18 2*2 1 1
213 SULOCHANA K 6 36 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
214 RASU K. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
215 MANICKAM M 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
216 PANJAVARNAM R. 6 60 1,5 2 2 6 36 1,5 2 2 6 36 2*3 1 1
217 LAKSHMI S. 6 36 1 2 2 6 36 1 2 2 6 36 3*2 1 1
218 VALLIAPPAN P. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
219 MURUGAN S. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
220 SOUNDARAJAN K. 6 36 1,2 2 2 6 36 1,2 2 2 6 18 2*1 1 1
221 PALANIAMMAL 6 6 1 1 2 6 6 1 1 2 6 6 1*1 1 1
222 CHINNAMMAL V. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
223 POUN M. 6 6 1 1 2 6 6 1 1 2 6 6 1*1 1 1
224 ANTONY DOSS A. 6 60 1,3 3 2 6 60 1,3 3 2 6 60 2*3 1 1
225 KALIYATHAL K. 6 60 1 2 2 6 60 1 2 2 6 60 3*3 1 1
226 VIJAYAMMA HM 1,2,5 3 2 HM 1,2,5 3 2 HM 4*4 1 1
227 VALLIAMMAL K. 6 60 1 2 2 6 60 1 2 2 6 60 3*2 1 1
228 MARIAPPAN P. 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
229 VIJAYALAKSHMI A. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
230 VEL MURUGAN 6 18 1,5 2 2 6 18 1,5 2 2 6 18 1*2 1 1
231 PALANISAMY V. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*1 1 1
232 MURASOLI R. FCF 1,2,5 4 1 1 FCF 1,2,5 4 1 FCF 0 4 0
233 POTTU M. HM 1,2,5 3 2 HM 1,2,5 3 2 HM 6*6 1 1
234 RAYAPPAN S. 6 60 1,5 3 2 6 12 1,5 3 2 6 12 2*2 1 1
235 MEENA R. 6 60 1,2 2 2 6 36 1,2 2 2 6 36 2*3 1 1
236 SUBBULAKSHMI S. HM 1,2,5 3 2 HM 1,2,5 3 2 1 1 HM 0 5 0
237 VENKATAIAH P. 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*1 1 1
238 MUSALAIAH V. 6 36 1,5 2 2 6 18 1,5 2 2 6 18 1*2 1 1
239 SUBRAMANIYAM ACHARI K. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
240 MURUGATHAL V. 6 60 1,5 2 2 6 60 1,5 2 2 6 60 3*3 1 1
241 MARIYA AROCKIAM K. PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
242 THAYAMMAL C. 6 36 1,5 2 2 6 36 1,5 2 2 6 36 2*2 1 1
243 DHANALAKSHMI K. 6 60 1 2 2 6 60 1 2 2 6 24 2*2 1 1
244 PANDIAN M. 6 36 1,5 2 2 6 18 1,5 2 2 6 18 4*2 1 1
245 DAGGUPATI SUBBAIAH 6 60 1,5 2 2 6 60 1,5 2 2 6 12 3*3 1 1
246 SRIDHAR R. 6 36 1,2 2 2 6 24 1,2 2 2 6 24 2*2 1 1
247
BOPPANA CHINA 
VENKATESWARLU 6 24 1 2 2 6 24 1 2 2 6 24 2*1 1 1
248 CHELLATHAL K. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
249 NATESAPILLAI T. 6 18 1 2 2 6 9 1 2 2 6 9 1*1 1 1
250 SANKARALINGAM I. 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
251 CHINNAPILLAI R. 6 24 1 2 2 6 24 1 2 2 6 24 1*2 1 1
252 CHINNAMMAL S. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
253 KUMAR M. 6 9 1,5 2 2 6 9 1,5 2 2 6 9 1*1 1 1
254 AYYAKALAI 6 12 1,5 2 2 6 12 1,5 2 2 6 12 1*2 1 1
255 KATHAMMAL N. HM 1,2,5 3 2 HM 1,2,5 3 2 HM 4*4 1 1
256 NAGARAJ R. 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
257 VIJAYALAKSHMI B. 5 60 1,5 2 2 5 60 1,5 2 2 6 24 2*2 1 1
258 SELVARAJ 2 60 1,2,5 3 2 2 60 1,2,5 3 2 2 60 4*4 1 1
259 RAJENDRAN T. PL 1,2,5 3 2 PL 1,2,5 3 2 PL 6*6 1 1
260 PANJAVARNAM R. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
261 SENTHAMARAI KANNAN R. 6 60 1,2 3 2 6 60 1,2 3 2 6 60 3*3 1 1
262 PERUMAL K. 5 60 1,2,5 2 2 6 60 1,2,5 2 2 6 60 4*3 1 1
263 SEETHAIYAMMAL R. 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
264 IBRAHIM SHA S. 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
265 NAGAMMA N. 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
266 MANI R. 1 60 1,2,5 3 2 1 60 1,2,5 3 1 1 1 60 0 4 0
267 RAVICHANDRAN 6 36 1,2 2 2 6 36 1,2 2 2 6 12 2*1 1 1
268 ARUMUGAM A. 6 18 1 2 2 6 12 1 2 2 6 12 1*1 1 1
269 DHASTHAGIRI G. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
270 TAJ NISHA.H 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
271 POLA SETTI KOTTESWARA RAO 6 36 1,5 2 2 6 12 1,5 2 2 6 12 2*2 1 1
272 MURUGANATHAN HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
273 THIRUMURUGAN T. 6 60 1,5 3 2 6 60 1,5 3 2 6 60 2*2 1 1
274 MUTHURAJ A. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
275 NAMBURANI P. 6 12 1,5 2 2 6 12 1,5 2 2 6 12 1*1 1 1
276 DHANALAKSHMI M. 6 9 1,5 2 2 6 9 1,5 2 2 6 9 1*2 1 1
277 SEENIVASAN T. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
278 RABIYA M. 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
279 IRULRAJA P. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
280 MUNIAMMAL K. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
281 MOOKKAMMAL 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
282 NEELA MEGAM M. 6 18 1 2 2 6 18 1 2 2 6 18 2*2 1 1
283 KADIRI NAGAMMA 6 24 1,3 2 2 6 24 1,3 2 2 6 24 2*3 1 1
284 ANDAL PL 1,2,5 3 2 PL 1,2,5 3 1 1 1 PL 0 4 0
285 SIVARAMAN K. HM 1,2,5 3 2 HM 1,2,5 3 2 HM 5*5 1 1
286 MURUGAIAH 6 60 1,2 2 2 6 60 1,2 2 2 6 36 2*2 1 1
287 ELUMALAI A. 6 60 1,2 2 2 6 60 1,2 2 2 6 60 2*3 1 1
288 RAMASAMY V. 6 36 1,5 2 2 6 36 1,5 2 2 6 36 3*3 1 1
289 KANNADASAN S. PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
290 PARIMALA 6 60 1,2 2 2 6 24 1,2 2 2 6 24 2*3 1 1
291 ESWARI V. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
292 BALAKRISHNAN D. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
293 MALAR KODI J. PL 1,2,5 3 2 PL 1,2,5 3 2 PL 5*6 1 1
294 KALIAMAML P. 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
295 MATHAMMAL V. 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
296 MARIAMMAL S. 6 12 1,5 2 2 6 12 1,5 2 2 6 12 2*1 1 1
297 PALANISAMY 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
298 MAYANDI R. 6 60 1,2 3 2 6 60 1,2 3 2 6 60 4*4 1 1
299 MAHALINGAM M. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
300 MAHALINGAM M. 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*2 1 1
301 NAGAMMA K. 6 12 1 2 2 6 9 1 2 2 6 9 1*1 1 1
302 KANNAN D. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
303 KALIMUTHU M. HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
304 NITHISH KUMAR S. 6 36 1,5 2 2 6 36 1,5 2 2 6 36 2*2 1 1
305 LAKSHMI R. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
306 SASTIVEL M.A. 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*2 1 1
307 RAJU A. 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
308 AYOTHI RAMAN K. 6 12 1 2 2 6 6 1 2 2 6 6 1*1 1 1
309 BALAMURUGAN G. HM 1,2,5 3 2 HM 1,2,5 3 2 HM 5*5 1 1
310 PETCHIAMMAL 6 60 1,5 2 2 6 60 1,5 2 2 6 60 4*2 1 1
311 SUBBAIAH M 6 12 1 2 2 6 12 1 2 2 6 9 2*1 1 1
312 NALLAMMAL .R 6 24 1 2 2 6 24 1 2 2 6 24 2*1 1 1
313 SEENIAMMAL K. 5 60 1,5 2 2 5 60 1,5 2 2 5 60 4*4 1 1
314 DEIVANAI 6 12 1 2 2 6 12 1 2 2 6 12 2*2 1 1
315 LAKSHMI J. 6 36 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
316 VADIVEL P. 6 18 1,5 2 2 6 18 1,5 2 2 6 18 2*1 1 1
317 MADHUSUDHAN 3 60 1,2,5 3 2 3 60 1,2,5 3 2 6 60 4*4 1 1
318 RASU E. 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*1 1 1
319 SANGEETHA R. 6 12 1,5 2 2 6 12 1,5 2 2 6 12 1*1 1 1
320 SUBBARAYUDU 6 24 1 2 2 6 12 1 2 2 6 12 2*2 1 1
321 BOSE PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
322 MURUGATHAL M. 6 60 1,3 2 2 6 60 1,3 2 2 6 60 3*3 1 1
323 ALAGAN L. 5 60 1,2 2 2 6 60 1,2 2 2 6 60 3*3 1 1
324 NATARAJAN R. 6 18 1 2 2 6 12 1 2 2 6 12 1*1 1 1
325 PAKKIRAMMA HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
326 THATHAR GOUNDAR 6 60 1 3 2 6 60 1 3 2 6 60 2*2 1 1
327 PITCHAIAMMAL G. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
328 GANGA BHAVANI 6 24 1 2 2 6 24 1 2 2 6 24 1*2 1 1
329 PONNAMMAL R. 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
330 BALKEES BEEVI 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
331 SUNTHARI HM 1,2,5 3 2 HM 1,2,5 3 1 1 HM 0 4 0
332 CHINNA SUBBAIAH T. 6 36 1,2 2 2 6 36 1,2 2 2 6 36 3*2 1 1
333 AMSATHAL K. 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
334 MURUGAN 6 24 1,2 2 2 6 12 1,2 2 2 6 12 1*1 1 1
335 THANGARAJ A. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
336 ANEESH SIVANANDAN 6 12 1 2 2 6 12 1 2 2 6 12 1*2 1 1
337 BALAYAPALLI SUJATHA 6 60 1,5 2 2 6 60 1,5 2 2 6 60 2*2 1 1
338 PAPPAYEE 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*2 1 1
339 KUPPUSWAMI C. HM 1,2,5 3 2 HM 1,2,5 3 1 1 HM 0 5 0
340 RAVI D. 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*1 1 1
341 SURIYAKALA K 6 18 1,2 2 2 6 18 1,2 2 2 6 18 1*1 1 1
342 SANGARA NARAYANAN S. 6 24 1 2 2 6 12 1 2 2 6 12 1*1 1 1
343 PENCHALAIAH PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
344 THANGA RAJ 5 60 1,2,5 2 2 5 60 1,2,5 2 2 5 60 4*3 1 1
345 KRISHNAVENI S. 6 24 1,2 2 2 6 24 1,2 2 2 6 24 2*2 1 1
346 MUTHUSAMY M. 6 60 1,2 3 2 6 60 1,2 3 2 6 60 2*2 1 1
347 PAPPA R. PL 1,2,5 3 2 PL 1,2,5 3 2 PL 4*4 1 1
348 MURUGAN V. 6 12 1,2 2 2 6 9 1,2 2 2 6 9 2*1 1 1
349 ASWATHI KIRUBAA 6 60 1,2 2 2 6 60 1,2 2 2 6 60 2*2 1 1
350 PANCHAVARNAM 6 24 1 2 2 6 24 1 2 2 6 24 2*2 1 1
351 LAKSHMI A 6 36 1,2 2 2 6 36 1,2 2 2 6 36 2*2 1 1
352 BYROS KHAN R HM 1,2,5 2 2 HM 1,2,5 2 1 1 HM 0 4 0
353 JANGAM REDDY 6 36 1 2 2 6 36 1 2 2 6 18 1*1 1 1
354 ALAGAMMAL 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
355 ANANTHAN R. 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
356 MUTHAMMAL M. 6 9 1,2 2 2 6 9 1,2 2 2 6 9 1*1 1 1
357 CHANDRASEKARAN K. 6 60 1 2 2 6 60 1 2 2 6 60 2*2 1 1
358 VIVEKANANDAN G. 6 60 1,5 2 2 6 36 1,5 2 2 6 36 2*2 1 1
359 AJITH S. 2 60 1,5 3 2 5 60 1,5 3 2 5 60 2*2 1 1
360 SUBBAMMA 6 60 1,2 3 2 6 60 1,2 3 2 6 60 2*2 1 1
361 MURUGESAN K 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
362 DHANAPALAN P. 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
363 ABISHEK M. 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
364 RASATHI 6 6 1,5 1 2 6 6 1,5 1 2 6 6 1*1 1 1
365 THANGAM G. 6 36 1,5 2 2 6 36 1,5 2 2 6 36 2*2 1 1
366 RAMAR P. 6 36 1,2 2 2 6 12 1,2 2 2 6 12 2*1 1 1
367 MURUGAPPAN 6 18 1 2 2 6 18 1 2 2 6 18 1*2 1 1
368 SUBRAMANI R. 6 60 1,2 2 2 6 60 1,2 2 2 6 60 3*3 1 1
369 RAM THAI 6 60 1,5 2 2 6 60 1,5 2 2 6 60 3*2 1 1
370 THANKA R. 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*1 1 1
371 ALAGUTHAI.R HM 1,2,5 4 1 1 HM 1,2,5 4 1 HM 0 4 0
372 MUTHU MURUGAN K. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
373 PITCHAI A. 4 60 1,2,5 3 2 4 60 1,2,5 3 2 4 60 3*4 1 1
374 AMEENA J. 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
375 RAVI K. 6 24 1 2 2 6 12 1 2 2 6 12 2*2 1 1
376
YANAMALA LAKSHMI 
NARAYANA 6 24 1,5 2 2 6 24 1,5 2 2 6 24 2*3 1 1
377 SAKTHIVEL M. 6 36 1,5 2 2 6 36 1,5 2 2 6 36 3*2 1 1
378 LAKSHMI DEVI 6 60 1 2 2 6 60 1 2 2 6 24 2*2 1 1
379 MATHAVANAI P. 6 18 1,5 2 2 6 12 1,5 2 2 6 12 1*2 1 1
380 RAJAMANICKAM 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
381 RATHINAM S. 6 12 1,2 2 2 6 12 1,2 2 2 6 12 1*1 1 1
382 JEYA PRAKASH R. 6 12 1,2 2 2 6 12 1,2 2 2 6 12 1*2 1 1
383 ANANDHARAJ L. 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
384 RAMANAIAH 6 60 1,5 3 2 6 60 1,5 3 2 6 60 2*2 1 1
385 SAMI 6 60 1 2 2 6 60 1 2 2 6 36 2*2 1 1
386 TAMILARASAN P. 6 12 1,2 2 2 6 12 1,2 2 2 6 12 2*2 1 1
387 ALAGU VEL 6 36 1 2 2 6 24 1 2 2 6 24 2*2 1 1
388 SHANMUGARAJ S. 6 60 1,5 2 2 6 60 1,5 2 2 6 60 3*3 1 1
389 MEENA S. 6 12 1 2 2 6 12 1 2 2 6 12 2*1 1 1
390 AYYAKANNU V HM 1,2,5 4 2 1 1 HM 1,2,5 4 2 HM 0 4 0
391 MOHAN RAJ 6 60 1 3 2 6 60 1 3 2 6 60 2*2 1 1
392 GOVINDHARASU G. 6 18 1 2 2 6 18 1 2 2 6 18 1*1 1 1
393 SILVAR STAR S 6 24 1,5 2 2 6 24 1,5 2 2 6 24 3*3 1 1
394 BANDISELLA BRAMAIAH 6 24 1 2 2 6 12 1 2 2 6 12 2*1 1 1
395 YOGESHWARAN 6 36 1 2 2 6 36 1 2 2 6 36 2*2 1 1
396 PANCHAVARNAM 6 60 1,5 2 2 6 60 1,5 2 2 6 60 3*3 1 1
397 IRUDHAYARAJ S. PL 1,2,5 4 1 1 PL 1,2,5 4 1 PL 0 4 0
398 VADIVEL C. 6 24 1 2 2 6 24 1 2 2 6 24 2*2 1 1
399 ALAGAMMAL C. 6 9 1 2 2 6 9 1 2 2 6 9 1*1 1 1
400 MURUGESWARI R. 6 24 1,5 2 2 6 18 1,5 2 2 6 18 1*2 1 1
401 GURUMURUGAN B. 6 9 1 1 2 6 9 1 1 2 6 9 1*1 1 1
402 CHINNAMMAL R. 6 24 1 2 2 6 24 1 2 2 6 24 1*2 1 1
403 SHAIK KHADAR MASTAN 6 12 1 2 2 6 12 1 2 2 6 12 1*1 1 1
404 LAKSHMI M. 6 60 1,5 2 2 6 36 1,5 2 2 6 18 1*1 1 1
CODING SHEET
MALE 1
GENDER FEMALE 2
20-30 1
31-40 2
AGE 41-50 3
51-60 4
61-70 5
AGRICULTURE WORKER/ F 1
LABOURER 2
OCCUPATION TRADESMAN/ PROFESSIO 3
UNEMPLOYED 4
RIGHT EYE 1
EYE LEFT EYE 2
YES 1
TRAUMA NO 2
VEGETABLE MATTER 1
THORN OR TREE BRANCH 2
MODE OF TRAUMA ANIMAL MATTER 3
DUST 4
FINGERNAIL 5
OTHERS 6
DM 1
HTN 2
SYSTEMIC BOTH DM AND HTN 3
NIL 4
YES 1
RECENT TOPICAL NO 2
RECENT SYSTEMIC YES 1
NO 2
MOTHER'S MILK 1
RECENT NATIVE MEDS OIL 2
CHICKEN BLOOD 3
TONGUE 4
NIL 5
YES 1
OCULAR SX NO 2
HYPOPYON YES 1
NO 2
FUSARIUM 1
CULTURE ASPERGILLUS 2
0- 33% 2
DEPTH 34-67% 3
68-100% 4
SMEAR FUNGUS PRESENT 1
FUNGUS ABSENT 2
NATAMYCIN 1
RX VORICONAZOLE 2
ITRACONAZOLE 5
PERFORATION YES 1
NO 2
IMPENDING PERFORATION YES 1
NO 2
WORSENING OF ULCER YES 1
NO 2
TPK DONE YES 1
NO 2
HEALED 1
IMPRESSION HEALING 2
REMAINED SAME 3
WORSENED 4
HEALED WITH ONE DRUG 1
HEALED WITH TWO DRUGS A 2
HEALED WITH TWO DRUGS B 3
HEALED WITH MORE THAN TWO DRUGS 4
